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To analyse the influence of mitochondrial genome variation on 
the DNA methylome of articular cartilage 
Methods
DNA methylation profiling was performed from data deposited in 
the NCBI Gene Expression Omnibus (GEO) database (accession 
number GSE43269) consisted in the data of 14 haplogroup J cartilages 
and 20 H cartilages. Subsequent validation was performed in an 
independent subset of 7 haplogroup J cartilages and 9 H cartilages by 
RNA-seq. Correlated genes were validated by real-time PCR in an 
independent cohort of 12 J cartilages and 12 H cartilages. Appropriate 
analytical analyses were performed using R bioconductor and qBase 
plus software, and gene ontology analyses were conducted using 
DAVID v6.8 
Results
DNA methylation profiling revealed 538 differentially methylated 
loci (DML) between H and J cartilages, whilst whole-transcriptome 
profiling identified 2384 differentially expressed genes between H and J 
cartilages. 17 genes showed an inverse correlation between 
methylation and expression. In terms of gene ontology, negative 
correlations between methylation and expression were also detected 
between H and J cartilages; highlighting a significantly enhanced and 
repressed apoptotic process in H and J cartilages respectively, as well 
as a significant enrichment of genes related to metabolic process and 
regulation of gene expression, in H cartilages, and to developmental 
process in J cartilages.
Conclusion
Mitochondrial DNA variation differentially associates with the 
methylation status of articular cartilage by acting on key mechanisms 
involved in OA, such as apoptosis, metabolic and developmental 
processes. 
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Osteoarthritis (OA) is a chronic progressive disorder that involves 
movable joints and is characterised by cell stress and extracellular 
matrix degradation initiated by micro- and macro-injuries that activate 
maladaptive repair responses including pro-inflammatory pathways of 
innate immunity. The disease manifests first as a molecular 
derangement (abnormal tissue metabolism) followed by anatomical 
and/or physiological derangements (characterised by cartilage 
degradation, bone rem delling, osteophyte formation, joint inflammation 
and loss of normal joint function) that can culminate in illness (1). OA is 
a heterogeneous disease, with a combination of modifiable factors, 
such as body mass index or joint injury, and non-modifiable factors like 
age, gender or genetics. 
In recent years, the study of epigenetics in OA attracted 
increasing interest. The term epigenetics refers to heritable changes in 
gene expression without changes in the DNA sequence, either by 
affecting gene transcription or by acting post-transcriptionally. Among 
the best characterized epigenetic mechanisms, DNA methylation stand 
out. It has been proposed that DNA methylation is involved in the 
phenotypic modulation that articular chondrocytes experience during 
the development of OA, leading to an over-expression of cartilage-
degrading enzymes and inflammatory mediators, breaking the 
homeostatic balance towards extracellular matrix degradation and 
playing a decisive role in the progression of the disease (2, 3). 
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Initial DNA methylation studies in OA were based on the study of 
specific CpG sites within the promoter region of OA-related genes, 
mainly cartilage-degrading enzymes (2, 4-7). More recently, genome-
wide DNA methylation analyses in OA have also been performed. 
These studies included the analysis of the methylome of 
cartilage/chondrocyte, the subchondral bone as well as human 
mesenchimal stem cells (hMSCs) from femoral heads of patients with 
hip fractures (8). From these studies, interesting conclusions can be 
drawn; on the one hand, hip and knee cartilage show different DNA 
methylomes (9) and even OA patients with the same affected joint can 
have different methylomes too; more specifically, a subgroup of OA 
patients with altered methylome in inflammation-related genes was 
independently identified (9, 10). On the other hand, the presence of an 
epigenetic phenotype associated with eroded OA subchondral bone 
similar to that of overlying eroded OA cartilage was also suggested 
(11), and hMSCs from OA patients with hip fractures showed 
accelerated methylation aging and enhanced proliferation of the 
osteogenic drivers RUNX2/OSX (12). Altogether, these works evidence 
the complexity of OA that includes complex genetic-epigenetic 
interactions and therefore further efforts must be done in order to clarify 
the role played by epigenetics in this disease (13). 
Mitochondria and the mitochondrial DNA (mtDNA) haplogroups 
play a role in the pathogenesis of OA (14). Specifically, the mtDNA 
haplogroups influence the prevalence of OA in different geographic 
populations (15-17) as well as the radiographic progression and 
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cartilage integrity over time in patients of the progression subcohort of 
the Osteoarthritis Initiative (18, 19). A recent meta-analysis involving 
more than 3000 subjects concluded that mtDNA haplogroups 
significantly influence the rate of incident knee OA; specifically, those 
subjects harboring haplogroup J show a significant decreased risk of 
developing incident knee OA at 8 years compared with subjects 
harboring haplogroup H, a different haplogroup in terms of ROS and 
ATP production, mitochondrial metabolism and apoptosis (20). 
The function of the mitochondria is controlled by the nucleus by 
means of an “anterograde regulation”, a mechanism that regulates both 
mitochondrial biogenesis and activity to meet the needs of the cell; on 
the other hand, mitochondria and mtDNA variation maintain partial 
regulatory signaling control over the nuclear epigenome, modulating the 
expression of nuclear genes through a “retrograde regulation”, a 
response signaling mechanism that leads to the modification of cellular 
function by reprogramming its metabolism (21, 22). The role of this 
bidirectional communication between nucleus and mitochondrion is not 
only to maintain cellular homeostasis, but also regulate the adaptation 
to a wide range of stressors (23).
In the light of these evidences and, given the demonstrated role 
of the mitochondria and mtDNA variation in OA, in this study we 
analyze the methylation data of cartilage samples carrying the mtDNA 
haplogroups H and J from our previously published genome-wide 
methylation assay (10) in order to check the influence of the mtDNA 
haplogroups on the DNA methylome of articular cartilage.
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DNA methylation profiling. DNA methylation profiling was 
performed using previous methylation raw data deposited in the NCBI 
Gene Expression Omnibus (GEO) database 
(http://www.ncbi.nlm.nih.gov/geo/), with accession number GSE43269 
(10). These data were obtained using the Infinium HumanMethylation27 
beadchip (Illumina, San Diego, CA, USA), which allows interrogation of 
27,578 highly informative CpG sites located within the proximal 
promoter regions of 14,495 genes and 110 microRNAs. We collected 
the methylation data from 14 J cartilage samples and 20 H (Table 1) to 
subsequently perform the appropriate differential analyses between 
these two haplogroups.
Data filtering, normalization and analysis of methylation 
data. The detection p-values measure the difference in signal 
intensities between the interrogated CpG site and those from a set of 16 
negative control probes embedded in the assay. Therefore, those 
samples with a detection p-value greater than 0.05 in more than 25% of 
all probes were considered as not significantly different from 
background noise, and removed from subsequent analyses as an extra 
quality control measure. Besides, those probes that were designed for 
sequences on X and Y chromosomes were also excluded.
We used M-value defined by Lumi and Methylumi package (R, 
Bioconductor) for differentially methylated analysis between mtDNA 
haplogroups H and J. M-value, which is the log2 ratio of methylated 
probe intensity and unmethylated probe intensity, is a method used to 
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measure the methylation levels and is homoscedastic in the entire 
methylation range, therefore being more statistically valid in differential 
and other statistical analysis (24, 25).
As a result of data filtering, one sample carrying the mtDNA 
haplogroup J obtained a detection p-value > 0.05 in more than 25% of 
all probes, being consequently removed from further analyses. 
Differentially methylated (DM) sites among mtDNA 
haplogroups. Statistical analysis and data visualization were carried 
out using the R/Biocoductor software packages 
(http://www.bioconductor.org). DNA methylation M-values of selected 
probes were compared among mtDNA haplogroups using ANOVA 
(Analysis of Variance) with Multcomp package. The analysis was 
adjusted for confounder effects of age, gender and disease status. As a 
consequence, to prevent the increase of type I error, Bonferroni 
correction was used to analyze specific haplogroup differences between 
H and J variants (26). CpGs sites were considered significantly 
differentially methylated if Bonferroni adjusted p-value was below 0.05. 
 The Illumina Infinium DNA methylation β-values were 
represented graphically using heatmaps generated by the 
R/Bioconductor packages heatmap and Heatplus.
RNA-seq. Knee cartilage samples for gene expression through 
RNA-seq (Table 1) were obtained from Hospital Universitario A Coruña. 
OA and healthy cartilages were obtained from autopsies or leg 
amputations, showing a microscopic Mankin score > 7 and < 2.5 
respectively. All cartilage samples were collected from the central area 
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of the tibial plateau of the knees, and represent a mixture of superficial, 
intermediate and deep layers of the articular cartilage. Informed consent 
was obtained from all participants in compliance with the Helsinki 
declaration, and this study was approved by ethics committee of 
Galicia. 
The whole RNA-seq process was carried out at Progenika 
Biopharma facilities (www.progenika.com). Genome-wide transcriptomic 
analysis was performed in a set of 7 haplogroup J cartilage samples 
and 9 haplogroup H cartilage samples (Table 1). For RNA isolation, 
cartilage samples (50-70 mg) were disrupted using a mortar, after 
freezing in liquid nitrogen before using the RNeasy Mini Kit (Qiagen, 
Duesseldorf, Germany) following manufacturer recommendations. RNA 
concentration was assessed using Nanodrop ND-1000 
spectrophotometer (Thermo Scientific, Wilmington, DE) and RNA 
quality was determined with the Agilent 2100 Bioanalyzer (Agilent, 
Santa Clara, CA).
Sequencing cDNA libraries were prepared from 30 ng RNA using 
Ovation Universal RNA-seq System 1-16 and Ovation Universal RNA-
seq Adaptor Module 1-16 (NuGen, San Carlos, CA) following 
manufacturer recommendations. The quality of the obtained cDNA 
library was then checked with both Qubit (Invitrogen, ThermoFisher, 
Wilmington, DE) and Agilent 2100 Bioanalyzer (Agilent, Santa Clara, 
CA) using the High Sensitivity DNA Analysis kit.
After the generation of the clusters inside the flow cell, a high 
density of molecules/cm2 on each cluster was subsequently generated; 
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therefore the samples were then sequenced in an Illumina HiSeq 4000 .
Differential analysis of RNA-seq data. Classically, the analysis 
of RNA-seq data includes the alignment of the obtained reads to a 
reference transcriptome followed by the quantification of the different 
transcripts. In this work we used the Kallisto method (27), and the RNA-
seq reads were mapped to the reference genome GRCh38 version 88 
located in Ensembl server (www.ensembl.org). All the reads were 
previously analysed with FastQC package 
(www.bioinformatics.berabaham.ac.uk/projects/fastqc) in order to 
perform the pre-treatment and to check the quality control.
To quantify the abundance of a transcript at genetic level we 
used Tximport package (28) included in R Bioconductor software 
(https://cran.r-project.org), using “transcripts per million” (TPM) as a 
quantification unit. Differential expression analyses between 
haplogroups H and J were performed following the limma-voom method 
(29) included in R Bioconductor software. A model including the 
haplogroup, as independent variable, and diagnosis, gender and age as 
covariables, was performed to detect the differentially expressed genes 
between haplogroups H and J.
Genes with a Benjamini-Hochberg (B-H) adjusted p-value <0.05 
were considered significantly differentially expressed between 
haplogroups H and J. Differentially expressed genes were visualized 
using volcano plots and heatmaps.
To identify the overlapped genes with inverse correlation 
between methylation and expression we crossed the significant genes 
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and DMLs of both assays, as described in other studies (30).
Gene ontology (GO) analyses. Functional characteristics 
consisting in an overrepresentation analysis of the GO categories which 
appeared significantly enriched in the selected lists of the differentially 
methylated/expressed genes between mtDNA haplogroups J and H 
were examined using DAVID (Database for Annotation, Visualization 
and Integrated Discovery) v6.8 (https://david.ncifcrf.gov/) bioinformatics 
database functional tool (31).
Real time-PCR validation. The expression levels of those genes 
in which an inverse relationship between methylation and expression 
was detected were subsequently analysed in knee cartilages from the 
central area of the tibial plateau (representing a mixture of superficial, 
intermediate and deep layers of the articular cartilage) belonging to an 
independent subset of 24 OA patients (12 haplogroup J and 12 
haplogroup H cartilages) from the same cohort (Table 1) using a 
Lightycler 480 II real time PCR system (Roche, Basel, Switzerland). 
The gene Beta-2 microglobulin (B2M) was used as a constitutive gene. 
The data analysis was carried out using qBase plus software 
(Biogazelle, Ghent University, Belgium).
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DNA methylation pattern in mtDNA haplogroups. The post-
hoc Bonferroni analysis revealed 538 DMLs between haplogroups H 
and J (Figure 1a) after adjusting for gender, age and disease status; of 
these, 451 were more methylated in J and 87 were less methylated in J 
in relation to the most common haplogroup H (Supplementary Table 1). 
A CpG site of fucosidase, alpha-L-1 (FUCA1) gene was the most 
differentially hypermethylated CpG, whilst the CpG site of homeobox D3 
(HOXD3) gene was the most differentially hypomethylated CpG in 
cartilages carrying the haplogroup J compared with cartilages carrying 
the most common haplogroup H.
The location of a CpG has important implications on its effect on 
gene expression; therefore we additionally explored the genomic 
location of the DMLs attending to the chromatin states described in the 
Roadmap Epigenomics Consortium (32). Most of the significant DMLs 
belong to active transcription start sites (TSS) (58.4%) or regions 
flanking active TSS (21.6%) and only 1.12% belong to enhancer 
regions (Supplementary Figure 1). Of them, the CpG site located in a 
region flanking the active TSS of FUCA-1 gene was, again, the most 
differentially hypermethylated CpG in carriers of the mtDNA J in relation 
to H; on the contrary, a CpG site located in the enhancer region of the 
RNASE8 gene was the most differentially hypomethylated CpG in 
carriers of the mtDNA haplogroup J in relation to H (Table 2).
When the gene ontology (GO) analysis was performed, the 
biological processes associated with significantly hypomethylated 
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genes in haplogroup J cartilages in relation to H were those related to 
the negative regulation of both the apoptosis (p=0.021) and the catalytic 
activity (p=0.035) as well as the developmental process (p=0.015); 
whilst the altered processes related to significantly hypomethylated 
genes in haplogroup H cartilages in relation to J were mainly those 
involved in cell death (p=0.010), the positive regulation of apoptosis 
(p=0.007), protein transport (p=0.007), metabolic processes (p=1.93e-4) 
as well as the regulation of cellular processes (p=0.009) and gene 
expression (p=0.012). In terms of molecular function, significantly 
hypomethylated CpGs in haplogroup J cartilages in relation to H were 
detected in genes related to the activity of transcription factors 
(p=0.019); on the contrary, the significantly hypomethylated CpGs in 
haplogroup H cartilages, in relation to J, were mainly those detected in 
genes related to nucleotide and metal ion binding (p=0.001 and 
p=0.043 respectively) (Figure 1b and 1c).
Among the DMLs involved in the differential regulation of 
apoptosis between H and J variants, those contained in DnaJ Heat 
Shock Protein Family (Hsp40) Member A3 (DNAJA3), nuclear factor of 
kappa light polypeptide gene enhancer in B-cells 1 (NFƙβ1) or cyclin-
dependent kinase inhibitor 2D (CDKN2B) genes appeared 
hypomethylated in J cartilages in relation to H; whilst those DMLs 
contained in janus kinase 2 (JAK2), lymphotosin alpha tumor necrosis 
factor superfamily, member 1 (LTA), ubiquitin B (UBB), complement 
component 9 (C9), insulin-like growth factor binding protein 3 (IGFBP3), 
tumor necrosis factor receptor-associated factor 3 (TRAF3) or Second 
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Mitochondria-Derived Activator Of Caspase (DIABLO) genes appeared 
hypomethylated in H cartilages in relation to J.
Whole-transcriptome analysis. Preliminary quality analyses 
lead to the removal of one of the samples; therefore the remaining 15 
were subjected to subsequent analyses. For the differential expression 
analysis, a total of 16,827 genes, with at least 1 TPM in 40% of the 
samples, were considered. 
The results obtained showed a total of 2384 differentially 
expressed genes between haplogroup H and J cartilages (Figure 2a 
and 2b), of which 2030 were significantly overexpressed in haplogroup 
J cartilages in relation to H, and 354 were significantly overexpressed in 
haplogroup H cartilages in relation to J (Supplementary Table 2). 
 The most differentially expressed genes between haplogroups H 
and J were FosB proto-oncogene, AP-1 transcription factor subunit 
(FOSB) gene and sodium Channel Protein Type 5 Subunit Alpha 
(SCN5A) gene; these genes appeared overexpressed in H cartilages 
and J cartilages respectively (Supplementary Table 2).
The GO analysis revealed differentially expressed processes, 
molecular functions and cellular components depending on the 
haplogroups (Figure 2c and 2d). In relation to J, H cartilages showed a 
significantly increased amount of genes related to nuclear part 
(p=4.61e-10) and membrane-enclosed lumen (p=1.85e-9); whilst in J 
cartilages, a significant enrichment of genes related to intrinsic 
component of membrane were over-expressed (p=1.67e-38). In terms 
of molecular functions, both haplogroups showed a differential profile; H 
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cartilages showed increased transcriptional repressor (p=0.027) and 
transcription factor activities (p=0.045), whilst J cartilages revealed an 
enrichment of genes related to ion transmembrane transporter activity 
(p=2.99e-4), mainly Calcium (p=6.81e-24). In relation to differentially 
altered biological processes, H cartilages showed an enrichment of 
over-expressed genes involved in RNA metabolic process (p=7.44e-5), 
mRNA splicing (p=3.89e-4) and gene expression, as well as metabolic 
process (p=6.79e-4) and, interestingly, cell death (p=0.019); conversely, 
J cartilages showed an enrichment of genes related to chemical 
synaptic transmission (p=1.56e-27), transmembrane transport 
(p=1.85e-22), especially Calcium (3.17e-4) and Potassium (p=1.62e-10) 
transport; as well as developmental process (p=8.25e-12).
In terms of relationships between methylation and expression, 
we detected a total of 46 overlapped genes between these two assays. 
Of these, 17 genes showed an inverse correlation between the two 
approaches, being 10 hypomethylated and up-regulated in haplogroup 
J cartilages in relation to H, whilst 7 were hypermethylated and down-
regulated in haplogroup J cartilages in relation to H (Table 2). The 
remainder 29 genes showed a direct correlation between methylation 
and expression. 
Real time-PCR validation. We validated, in an independent 
subset of 12 knee OA J cartilages and 12 knee OA H cartilages, the 17 
genes with inverse correlation between methylation and expression 
data (Table 2).
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Of all the 17 genes analysed, 6 showed no amplification in any of 
the samples. Of the remaining 11 genes, ATXN7 appeared significantly 
up-regulated (p=0.023) in haplogroup H cartilages compared with 
haplogroup J cartilages (Table 3).
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In the present study, we compared for the first time the DNA 
methylome of articular cartilages harbouring mtDNA haplogroups J and 
H, followed by a whole-genome transcriptome analysis by means of 
RNA-seq and subsequent real-time PCR validation of correlated genes. 
The results obtained show not only a differential methylation profile 
related to these haplogroups, but also correlations between methylation 
and expression in terms of gene ontology, such as apoptosis, 
developmental process, metabolic process or the regulation of gene 
expression. In terms of genes, a total of 17 showed an inverse 
correlation between methylation and expression.
Cartilages harbouring haplogroups J and H show a differential 
behaviour in terms of apoptosis, being this process enhanced in H 
cartilages and more repressed in J cartilages. Moreover, H cartilages 
also show an enrichment of overexpressed genes related to cell death. 
The relationship between mtDNA haplogroups and apoptosis is not 
new; a study by Kenney an co-authors showed that cybrids with 
haplogroup J had reduced expression of apoptosis-related genes than 
cybrids with haplogroup H (33). In addition, J cybrids also show a lower 
grade of apoptosis under stress conditions as well as a lower 
expression of the apoptotic gene BBC3 when compared with H cybrids 
(20). Altogether, these results evidence that inherited mitochondrial 
variants can affect apoptosis pathway and, since chondrocyte death is a 
central feature in OA progression (34, 35), this could explain, at least in 
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part, the associations of haplogroup J with the lower rate of knee and 
hip OA prevalence and incident knee OA (20, 36, 37).
In this study a significant enrichment of both overexpressed 
genes and hypomethylated CpGs of genes related to developmental 
process, including the homeobox family of transcription factor genes, 
was also detected in J cartilages in relation to H cartilages. These 
genes have been shown to play a key role in the regulation of 
embryonic development, morphogenesis, cellular proliferation and 
differentiation, and angiogenesis. A potential link between OA and 
homeobox transcription factors has been previously proposed (38) and, 
interestingly, genome-wide methylation studies performed in OA 
cartilage showed these kind of genes with altered methylation profile (9, 
10, 39). As for rs225014 and rs12885300 polymorphisms in DIO2 gene, 
a key regulator gene of the endochondral ossification process and 
whose relationship with OA pathology relies on its influence on skeletal 
formation (40), the findings of the present study could point to the 
importance of mitochondria in the developmental process, including cell 
differentiation, skeletal embryogenesis and even joint morphology, 
through the influence of mitochondrial genetic background on the 
methylation and expression patterns of this family of genes. Specifically, 
joint morphology is considered a relevant risk factor for OA 
development and progression (41), and differential expression of genes 
involved in skeletal formation was also found in OA affected cartilage 
(42).
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In terms of fold change, real time PCR validation showed that a 
total of 6 out of the 7 genes with inverse correlation between 
methylation and expression in haplogroup H cartilages were over-
expressed in this haplogroup; however, only ATXN7 (Ataxin 7) reached 
the statistical significance. ATXN7 is a transcription factor that appears 
to be critically important for chromatin remodelling at the level of histone 
acetylation and deubiquitination. This gene is involved in the 
development of spinocerebellar ataxia, a neurodegenerative disorder, 
although its role in OA is not known and requires further investigation. 
However, since this gene has been proposed to be involved in the 
mitochondrial apoptotic pathway through the activation of caspases -3 
and, more specifically -9 (43, 44), from these data would be conceivable 
that cartilages harbouring mtDNA haplogroup J are less prone to 
activate this pathway, in agreement with previous studies mentioned 
above in this manuscript.
Mitochondria exert a retrograde control over the nucleus through 
a series of signalling mechanisms that modify nuclear gene expression, 
leading to different compensatory mechanisms (45). The compensatory 
mechanisms may be induced in response to either mitochondrial 
dysfunction or mtDNA inherited variants (haplogroups), which are 
capable of alter the crosstalk signalling between the mitochondria and 
the nucleus, inducing nuclear compensation in the form of altering DNA 
methylation patterns and therefore gene expression (21). In agreement 
with this, not only are the results described in this work, but also other 
findings. Cybrids harbouring haplogroup J show increased levels of 
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global DNA methylation as compared with other mtDNA variants (46); in 
addition, both H and J haplogroups differentially mediate methylation 
profiles and transcription for inflammation and angiogenesis (47); and 
mouse embryonic stem cells containing different mtDNA haplogroups 
on a uniform nuclear background were associated with different gene 
expression and DNA methylation profiles (48).
In relation to the underlying mechanisms by which mitochondrial 
variation promote modifications in the methylome, it is conceivable that 
mitochondrial reactive oxygen species (ROS), small RNAs, 
mitochondria-derived peptides or reactive metabolic intermediates from 
the mitochondrial metabolism represent important retrograde signaling 
stimulus for nuclear epigenomic DNA modifications (21, 49, 50). Taken 
together, the findings provided in this work support the evidence of the 
mitochondrial genome as an epigenetic regulator of the nuclear genome 
in articular cartilage.
For this study we did not set a minimum differentially-
expressed/methylated ratio threshold, but we selected those loci with 
adjusted statistical significance, as described in other studies (30, 51). 
The methylation data have been obtained from an ancient array 
(Illumina HumanMethylation27 beadchip), that showed small significant 
methylation differences between haplogroups H and J. To what extent 
these differences are sufficient to induce changes in the expression 
pattern, it could by assessed by making the corresponding expression 
assay. In addition, it must be noted that other potential DMLs not 
included in this array could also contribute to induce changes in the 
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expression pattern. In this sense, the use of three different independent 
subsets of samples allowed us to detected 17 overlapping genes with 
an inverse correlation between methylation and expression, being one 
of them (ATXN7) statistically validated by real time PCR. This is 
interesting and contributes robustness to the study because it must be 
noted that not only the mitochondrial genome has the potential to 
induce changes in the methylation/transcription pattern of articular 
chondrocytes, but also other intrinsic factors related to the nature of the 
articular cartilage as well as the condition or state of the OA disease, 
even in terms of overlapped phenotypes, could also affect (9, 10, 52).
In summary, it is well established that mitochondrial function is 
vital to provide the intermediate metabolites necessary to generate 
epigenetic marks, including DNA methylation, in the nucleus (22). In this 
sense, two biochemically different mtDNA haplogroups, such as J and 
H (53, 54), are differentially associated with the methylation status of 
articular cartilage. We could hypothesize that the epigenetic 
modification that takes place in OA that affects key-related features, 
such as apoptosis or metabolic alterations, is different depending on the 
haplogroup. This could determine, to some extent, the evolution of the 
disease.
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Figure 1. Hierarchical analysis and potentially altered biological 
processes (GO) of the differentially methylation loci (DML) 
between haplogroup J and haplogroup H cartilages. a) Heatmap 
showing the 538 DMLs between haplogroup J cartilages and 
haplogroup H cartilages; b) GO analysis comparing the hypomethylated 
genes in haplogroup J cartilages related to haplogroup H cartilages; c) 
GO analysis comparing the hypomethylated genes in haplogroup H 
cartilages related to haplogroup J cartilages. ES: Enrichment Score. 
(***p≤0.0001; **p≤0.01; *p ≤0.05)
Figure 2. Hierarchical analysis and potentially altered biological 
processes (GO) of the differentially expressed genes between 
haplogroup J and haplogroup H cartilages. a) Volcano plot showing 
the differentially expressed genes between haplogroups H and J. Blue 
dots are over-expressed in H versus J, and red dots are genes over-
expressed in J versus H. b) Heatmap showing the 2384 differentially 
expressed genes between haplogroup J cartilages and haplogroup H 
cartilages; c) GO analysis comparing the over-expressed genes genes 
in haplogroup J cartilages related to haplogroup H; d) GO analysis 
comparing the over-expressed genes in haplogroup H cartilages related 
to haplogroup J. ES: Enrichment Score. (***p≤0.0001; **p≤0.01; *p 
≤0.05)
Supplementary figure 1.  Genomic location of DMLs between 
haplogroups H and J. Percentage of DMLs between haplogroups H 
and J on each of the genomic locations attending to the chromatin 
states described in the Roadmap Epigenomics Consortium. TssA: 
Active transcription start site; TssAFlnk: Transcription at gene 5´and 3´; 
TxFlnk: Strong transcription; TxWk: Weak transcription; Enh: 
Enhancers; TssBiv: Bivalent/Poised transcription start site; BivFlnk: 
Flanking bivalent Tss/Enh; ReprPC: Repressed PolyComb; ReprPCWk: 
Weak repressed PolyComb; Quies: Quiescent/low
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Table 1. Characteristics of the study population




Haplogroup H 20 67.1 ± 9.9 9 (45) / 11 (55) 12 (60) / 8 (40)
Haplogroup J 14 62.8 ± 9.5 7 (50) / 7 (50) 6 (42.9) / 8 (57.1)
RNA-seq cohort 16
Haplogroup H 9 66.1 ± 17.8 4 (44.5) / 5 (55.5) 5 (55.5) / 4 (44.5)
Haplogroup J 7 71.8 ± 11.3 3 (43) / 4 (57) 5 (71) / 2 (29)
Real-time PCR cohort 24
Haplogroup H 12 69.9 ± 9.4 8 (66.6) / 4 (33.3) 12 (100) / 0 (0)
Haplogroup J 12 69.6 ± 6.3 6 (50) / 6 (50) 12 (100) / 0 (0)
Values represent frequencies with percentage in parentheses; SD = standard deviation; OA: osteoarthritic 
patients
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Table 2. List of the 17 significant altered genes with inverse correlation between methylation and expression and associated biological processes

































AGL -0.0078 0.02027 -1.5453 0.04199 Metabolic process, Metal Ion binding ACE 0.0036 0.03551 4.5218 0.00122 Developmental process
ATXN7 -0.0096 0.04938 -1.4136 0.01058
Cell death, Metabolic 
process, Regulation of 
gene expression, Metal Ion 
binding, Cellular process
ADCY4 0.0044 0.04823 2.4765 0.01760 Negative regulation of catalytic activity
FPGS -0.0051 0.00230 -1.1650 0.04580 Metabolic process, Nucleotide binding EMX1 0.0047 0.04861 4.9444 0.00261
Developmental process, 
Transcription factor activity
GPR89B -0.0049 0.02138 -1.4849 0.04599 Cellular process GDNF 0.0117 0.04760 2.7488 0.04211 Developmental process, Cell communication
MCCC2 -0.0237 0.02628 -1.2505 0.04015 Metabolic process, Nucleotide binding GP2 0.0411 0.03345 2.7910 0.02197
Innate immune response, 
Antigen-binding
PPME1 -0.0047 0.03481 -1.2707 0.04480 Metabolic process INSL6 0.0715 0.03694 2.5185 0.00393 Developmental process
USP13 -0.0041 0.00902 -1.2209 0.02099
Metabolic process, 
Regulation of gene 
expression, Metal Ion 
binding
KCNIP4 0.0063 0.03051 4.0660 0.00993
Metal Ion binding, Calcium 
Ion binding, Cell 
communication
MMP8 0.0227 0.02569 3.9680 0.00811 Developmental process
OTOA 0.0516 0.00246 3.7502 0.00248 Developmental process, Cell communication
WT1 0.0151 0.04113 3.9396 0.03872
Developmental process, 
Transcription factor activity, 
Ion binding
(*) adjusted p-value calculated by Bonferroni method for false discovery rate control; (#) adjusted p-value calculated by Benjamini & Hochberg´s method for false discovery rate control; LogFc: 
log fold change
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Table 3. Mean expression levels of 11* genes with inverse correlation between methylation and expression in the real-time PCR cohort 
between 12 haplogroup J cartilages and 12 haplogroup H cartilages























AGL 1.429 0.615 3.321 0.335 ACE 0.348 0.072 1.680 0.054
ATXN7 2.373 0.977 5.766 0.023# ADCY4 1.384 0.477 4.019 0.464
FPGS 1.403 0.544 3.616 0.295 GDNF 1.105 0.146 8.380 0.304
MCCC2 1.413 0.530 3.770 0.221 INSL6 1.505 0.219 10.356 0.315
PPME1 1.215 0.636 2.321 0.511 MMP8 1.560 0.219 11.107 0.276
USP13 1.229 0.638 2.368 0.295
(*) Only those genes with positive real-time amplification (11/17) are shown; (#) p-value ≤ 0.05 after Mann-Whitney non-parametric test; CI: 
confidence interval. 
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Figure 1. Hierarchical analysis and potentially altered biological processes (GO) of the differentially 
methylation loci (DML) between haplogroup J and haplogroup H cartilages. a) Heatmap showing the 538 
DMLs between haplogroup J cartilages and haplogroup H cartilages; b) GO analysis comparing the 
hypomethylated genes in haplogroup J cartilages related to haplogroup H cartilages; c) GO analysis 
comparing the hypomethylated genes in haplogroup H cartilages related to haplogroup J cartilages. ES: 
Enrichment Score. (***p≤0.0001; **p≤0.01; *p ≤0.05) 
358x272mm (300 x 300 DPI) 
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Figure 2. Hierarchical analysis and potentially altered biological processes (GO) of the differentially 
expressed genes between haplogroup J and haplogroup H cartilages. a) Volcano plot showing the 
differentially expressed genes between haplogroups H and J. Blue dots are over-expressed in H versus J, 
and red dots are genes over-expressed in J versus H. b) Heatmap showing the 2384 differentially expressed 
genes between haplogroup J cartilages and haplogroup H cartilages; c) GO analysis comparing the over-
expressed genes genes in haplogroup J cartilages related to haplogroup H; d) GO analysis comparing the 
over-expressed genes in haplogroup H cartilages related to haplogroup J. ES: Enrichment Score. 
(***p≤0.0001; **p≤0.01; *p ≤0.05) 
358x272mm (300 x 300 DPI) 
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S1 Table. Significant DMLs between mtDNA haplogroups J and H sorted by decreased mean differences in β-values
Increased methylation in mtDNA haplogroup J in relation to H
 



































FUCA1 0.02777601 0.399312696 0.280808728 -0.118504 TssAFlnk HOXD3 0.00972604 0.598486681 0.702065414 0.10357873 ReprPC
SCGB3A2 0.0389597 0.463906683 0.376409848 -0.0874968 ReprPCWk C18orf22 0.0122295 0.44752513 0.540030453 0.09250532 TssAFlnk
BATF 0.0193415 0.400475125 0.313485669 -0.0869895 TssA RNASE8 0.01712879 0.4710678 0.563567625 0.09249982 Enh
SMAD9 0.02008177 0.652007037 0.569444743 -0.0825623 TxWk PXT1 0.01977422 0.480545025 0.560498861 0.07995384 Quies
PARG 0.0368257 0.51949802 0.440874968 -0.0786231 TxWk TMEM85 0.02167335 0.263073523 0.341621104 0.07854758 TssAFlnk
RP11-631M21.2 0.04585799 0.661697616 0.586322251 -0.0753754 ReprPC CUEDC1 0.00603239 0.756111604 0.827769409 0.07165781 TxWk
MAP3K7IP1 0.0021723 0.690737633 0.615472567 -0.0752651 Quies INSL6 0.03693925 0.670885926 0.742421783 0.07153586 ReprPCWk
CHRNB3 0.04619031 0.532840034 0.458801353 -0.0740387 ReprPCWk PARK2 0.02279648 0.562938798 0.62636458 0.06342578 ReprPCWk
C4orf50 0.04658875 0.258153918 0.185906253 -0.0722477 Quies TCP11 0.00026284 0.730426317 0.786807024 0.05638071 TxWk
MT2A 0.04679405 0.252876945 0.182187135 -0.0706898 TssAFlnk KCNN4 0.03873873 0.626915659 0.682008441 0.05509278 TxWk
GPR132 0.02500337 0.463643694 0.39315051 -0.0704932 Enh OTOA 0.00245835 0.631505306 0.683112724 0.05160742 ReprPCWk
JAK2 0.00504873 0.538640289 0.471831859 -0.0668084 TssAFlnk BTN3A2 0.04987696 0.637554195 0.68909609 0.0515419 TssAFlnk
MLLT6 0.0100727 0.177538577 0.11748274 -0.0600558 TssAFlnk RGSL1 0.04670961 0.73047679 0.781064602 0.05058781 ReprPCWk
MCCC1 0.04127632 0.20903379 0.150586743 -0.058447 TssA OR51B4 0.02404552 0.623224522 0.671966061 0.04874154 Quies
CIAO1 0.03075463 0.412039967 0.354504713 -0.0575353 TssAFlnk FHIT 0.04774361 0.137109412 0.18496194 0.04785253 TssA
EI24 0.00242219 0.141169571 0.086879903 -0.0542897 TssA HMGCL 0.00250927 0.853779851 0.896420626 0.04264077 TssA
KCNQ1 0.01608712 0.305409504 0.252345675 -0.0530638 TssAFlnk NLRP7 0.04142779 0.74225002 0.784692326 0.04244231 Quies
DCUN1D1 0.00337277 0.343221868 0.290481687 -0.0527402 TssA GYS1 0.0198018 0.026711751 0.068418035 0.04170628 TssA
SLC7A7 0.02832055 0.690309878 0.637837042 -0.0524728 TxWk GP2 0.03344997 0.776629295 0.817721131 0.04109184 Quies
HIGD1B 0.01818552 0.605133543 0.552813687 -0.0523199 TxWk RMND5B 0.04641332 0.471877493 0.511670905 0.03979341 TssAFlnk
LBP 0.04086789 0.770208099 0.718145059 -0.052063 ReprPC C9orf64 0.01785302 0.099988279 0.139696349 0.03970807 TssAFlnk
GALNT1 0.04346994 0.710678665 0.65961273 -0.0510659 Enh SLC3A1 0.00176583 0.769025352 0.808057052 0.0390317 TxWk
BECN1 0.00298449 0.14614909 0.095647577 -0.0505015 TssA LRTOMT 0.02260737 0.564218807 0.602164258 0.03794545 TssAFlnk
SMAD9 0.0051881 0.90175735 0.852180107 -0.0495772 Tx ZNF45 0.03127447 0.787693737 0.825397879 0.03770414 Tx
SCG2 0.00064486 0.168819108 0.119323823 -0.0494953 Enh PRAMEF1 0.01531912 0.706651253 0.742845395 0.03619414 Quies
MLC1 0.03227513 0.406694457 0.357306299 -0.0493882 TssAFlnk HIVEP3 0.02562103 0.078483213 0.114035763 0.03555255 TssAFlnk
GOLGA9P 0.04602977 0.800967558 0.754177343 -0.0467902 Quies PLA2G2D 0.02846063 0.832299523 0.867511682 0.03521216 ReprPC
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SEPT1 0.02487987 0.765500146 0.718814362 -0.0466858 Quies VAV1 0.03306356 0.309988851 0.344152147 0.0341633 ReprPCWk
ATP2C1 0.03747537 0.260341018 0.214084713 -0.0462563 TssA C20orf186 0.03395926 0.688218533 0.721833861 0.03361533 ReprPCWk
H6PD 0.03927231 0.382372132 0.336303129 -0.046069 TssAFlnk MACROD2 0.03868366 0.046309306 0.079640708 0.0333314 TssA
OCM2 0.04225779 0.73008521 0.685064662 -0.0450205 ReprPCWk ATAD2 0.01906732 0.047254264 0.077391554 0.03013729 TssA
LTA 0.04154666 0.687621462 0.643460132 -0.0441613 ReprPCWk KRTAP19-6 0.04791749 0.851254059 0.876441361 0.0251873 Quies
PPP2R4 0.01992989 0.473163979 0.430719258 -0.0424447 TssAFlnk SMPDL3A 0.01099343 0.116184657 0.140065683 0.02388103 TssA
NCRNA00175 0.02392877 0.867539252 0.826420213 -0.041119 Quies ZBTB8A 0.03871428 0.100757513 0.124133948 0.02337644 BivFlnk
SCN2A 0.0289227 0.282964737 0.243465874 -0.0394989 TssA CCDC57 0.0220344 0.038554517 0.061715292 0.02316078 TssA
ARF5 0.00718366 0.484080213 0.44598496 -0.0380953 TssAFlnk MMP8 0.02569413 0.783368309 0.806083587 0.02271528 ReprPCWk
GPR26 0.0310081 0.274979413 0.236933338 -0.0380461 ReprPC PBK 0.03973871 0.035818919 0.057644218 0.0218253 TssAFlnk
PRRC1 0.04270081 0.180375278 0.142409366 -0.0379659 TssAFlnk AADAC 0.02359167 0.880587594 0.901848197 0.0212606 Quies
CEACAM6 0.01669855 0.333204518 0.295602683 -0.0376018 ReprPCWk CHRNA1 0.01807859 0.906184679 0.926547632 0.02036295 Quies
CNGB3 0.01525879 0.861039103 0.823648064 -0.037391 Quies ARL11 0.03455042 0.870530924 0.88893985 0.01840893 Quies
CGB2 0.03990286 0.632652849 0.595263281 -0.0373896 Quies C1orf183 0.03888011 0.077542569 0.093474042 0.01593147 TssAFlnk
CRBN 0.01182991 0.188113697 0.150726969 -0.0373867 TssAFlnk AMY2B 0.04362334 0.908913606 0.924499085 0.01558548 Tx
THOP1 0.01158132 0.122685132 0.085362755 -0.0373224 TssAFlnk WT1 0.04112907 0.050797118 0.065877667 0.01508055 ReprPC
ALPPL2 0.04040121 0.809976358 0.772784789 -0.0371916 ReprPCWk MORN2 0.04058054 0.046936463 0.061726176 0.01478971 TssA
LEPR 0.01542529 0.166542865 0.129507388 -0.0370355 TssA STK17B 0.02256286 0.02702971 0.041646987 0.01461728 TssA
TMEM92 0.04792627 0.196370935 0.160660077 -0.0357109 Enh CPT1B 0.01651107 0.039439326 0.05306318 0.01362385 TssAFlnk
ABHD12B 0.00904213 0.823288755 0.787819225 -0.0354695 ReprPC LOC388428 0.00811788 0.037823522 0.051111122 0.0132876 ReprPC
ACP6 0.04053718 0.416501475 0.383081335 -0.0334201 TxWk MSX2 0.01282013 0.030345018 0.04228093 0.01193591 TssBiv
HLA-DRA 0.00857193 0.792671181 0.760332008 -0.0323392 ReprPCWk ZBED5 0.0491847 0.045391981 0.057188533 0.01179655 TssA
SP6 0.02831129 0.624097728 0.59196655 -0.0321312 ReprPCWk GDNF 0.04760486 0.042701431 0.054422101 0.01172067 TssAFlnk
CCDC82 0.03612089 0.094934119 0.062938062 -0.0319961 TssA KRCC1 0.04203367 0.047540696 0.058594616 0.01105392 TssA
SIT1 0.04505777 0.772682389 0.741102364 -0.03158 TxWk CHID1 0.00476953 0.031571075 0.042177567 0.01060649 TssAFlnk
TNNC2 0.03492048 0.819495715 0.788427384 -0.0310683 TxWk GNB2L1 0.01378364 0.050702105 0.060596868 0.00989476 TssA
NANOS1 0.0371908 0.255867537 0.22535853 -0.030509 TssAFlnk BBS10 0.04036868 0.026193923 0.035873037 0.00967911 TssA
CLEC2D 0.01369671 0.856343562 0.826412137 -0.0299314 TxWk DCST1 0.03462806 0.945808182 0.955299518 0.00949134 ReprPCWk
PFKM 0.02850575 0.817469372 0.788433882 -0.0290355 TxWk EIF4A3 0.0203592 0.038543476 0.047914477 0.009371 TssA
TFEC 0.02777643 0.157004403 0.129014455 -0.0279899 Enh GCOM1 0.04540071 0.035413238 0.044632082 0.00921884 TssA
KCNN4 0.01630544 0.11842198 0.091238725 -0.0271833 TssAFlnk SPOCK1 0.02696536 0.036294887 0.04538894 0.00909405 TssA
CTSO 0.00530965 0.086719641 0.059764406 -0.0269552 TssA NFKB1 0.01184187 0.050847328 0.059911212 0.00906388 TssA
ZNF114 0.00447904 0.081185672 0.054771786 -0.0264139 TssA UBAP2 0.04202495 0.037762288 0.045627223 0.00786494 TssA
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KIAA1191 0.04444128 0.108579344 0.082232094 -0.0263473 TssAFlnk RPL18A 0.04068076 0.048714733 0.056577929 0.0078632 TssA
DUSP12 0.00666076 0.120625031 0.094886878 -0.0257382 TssAFlnk FAT1 0.01819613 0.035798988 0.043056425 0.00725744 TssA
TNFSF13B 0.02223739 0.117144795 0.091482651 -0.0256621 TssAFlnk TNPO1 0.00013379 0.027692093 0.034877472 0.00718538 TssAFlnk
CDKAL1 0.02118422 0.11949895 0.093997714 -0.0255012 TssA NMD3 0.01645587 0.032498112 0.039519469 0.00702136 TssA
NUP214 0.01357438 0.156217639 0.131127305 -0.0250903 TssAFlnk ATP5F1 0.03123527 0.574925735 0.581865353 0.00693962 TssAFlnk
ZNF12 0.00466064 0.118223276 0.093641135 -0.0245821 TssAFlnk MIPEP 0.04127479 0.051499565 0.058434877 0.00693531 TssA
RRP15 0.04037583 0.117367783 0.092850757 -0.024517 TssA KCNIP4 0.03050876 0.063838153 0.070149367 0.00631121 Quies
PKP4 0.0185401 0.276214491 0.252446312 -0.0237682 TssA IHH 0.03610379 0.033806128 0.040012391 0.00620626 TssBiv
MCCC2 0.02628432 0.129649666 0.105944011 -0.0237057 TssAFlnk SEMA3C 0.0472525 0.035009309 0.0409549 0.00594559 TssA
ANKRA2 0.01826785 0.161939643 0.138318172 -0.0236215 TssA TRABD 0.01443755 0.031177957 0.037110165 0.00593221 TssA
SP100 0.01823025 0.12104041 0.097442751 -0.0235977 TssA PSD2 0.00576328 0.02647897 0.032331257 0.00585229 BivFlnk
DEFB1 0.0074216 0.900378325 0.87698702 -0.0233913 ReprPC IFT81 0.04147953 0.04379508 0.049370253 0.00557517 TssAFlnk
GSTP1 0.00741042 0.127578081 0.104214551 -0.0233635 TssAFlnk LGALS3 0.04370476 0.015914557 0.021489236 0.00557468 TssA
UBB 0.01826876 0.118438046 0.095113024 -0.023325 TssA INPP1 0.00599696 0.030820253 0.036337689 0.00551744 TssAFlnk
SACM1L 0.0264931 0.141304522 0.118168238 -0.0231363 TssA CDKN2D 0.03546617 0.046358779 0.051817342 0.00545856 TssAFlnk
DCDC1 0.00972762 0.113096546 0.090545831 -0.0225507 TssA DFNB31 0.01831463 0.024928539 0.030310255 0.00538172 TssA
LOC388428 0.04900847 0.584248246 0.561823596 -0.0224246 ReprPC RAB13 0.03212502 0.027535108 0.032739686 0.00520458 TssAFlnk
UFD1L 0.00177682 0.092737764 0.070484402 -0.0222534 TssA C16orf70 0.01634673 0.02104584 0.026249662 0.00520382 TssAFlnk
PIGB 0.02703708 0.071308384 0.049273113 -0.0220353 TssA E2F7 0.0433037 0.02744869 0.032555147 0.00510646 TssA
C9 0.03404764 0.90105839 0.879612419 -0.021446 Quies EMX1 0.04860867 0.028324145 0.033043429 0.00471928 ReprPC
TUBA1A 0.03296692 0.218534686 0.197223517 -0.0213112 TssA ADCY4 0.04823056 0.025038285 0.029424503 0.00438622 TssAFlnk
ACRBP 0.00271134 0.908022767 0.886885013 -0.0211378 Tx NFX1 0.01791818 0.024650232 0.02891902 0.00426879 TssA
C2orf44 0.02025651 0.088379364 0.067414327 -0.020965 TssA GSK3A 0.03454229 0.019259441 0.023381746 0.00412231 TssA
ESPL1 0.01447895 0.095881361 0.074970591 -0.0209108 TssA ACE 0.03551541 0.019937153 0.023554564 0.00361741 TssA
SPTBN2 0.03665397 0.899383278 0.878921867 -0.0204614 ReprPCWk DNAJA3 0.03547632 0.024008724 0.027615616 0.00360689 TssA
WHSC2 0.0266749 0.135753881 0.115416242 -0.0203376 TssAFlnk TECR 0.00995436 0.020387784 0.023458414 0.00307063 TssA
TWSG1 0.01477153 0.077472661 0.057729954 -0.0197427 TssAFlnk GSTM2 0.01634592 0.018959747 0.021528335 0.00256859 TssA
ACSBG2 0.0373333 0.87543063 0.855785676 -0.019645 Quies
TCEB1 0.04825173 0.097651759 0.078450727 -0.019201 TssA
MOCS1 0.03768025 0.90920213 0.890958014 -0.0182441 TxWk
NOL12 0.0042019 0.082621306 0.064493009 -0.0181283 TssAFlnk
RHBDD3 0.006972 0.092489242 0.075109723 -0.0173795 TssAFlnk
C16orf70 0.03161925 0.053987801 0.036630261 -0.0173575 TssA
Page 67 of 135
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
C6orf108 0.00353825 0.073582125 0.056282354 -0.0172998 TssAFlnk
TAF5 0.01233357 0.06378397 0.046606021 -0.0171779 TssA
BMI1 0.03977099 0.059560123 0.042499812 -0.0170603 TssA
HOXA9 0.02893433 0.075681989 0.058773833 -0.0169082 TssA
C1orf61 0.04102823 0.095798732 0.078914685 -0.016884 ReprPC
FDFT1 0.04751252 0.054325044 0.037461854 -0.0168632 TssA
SCGB2A2 0.03031629 0.840887446 0.824663857 -0.0162236 ReprPCWk
IDH3A 0.00605313 0.07646527 0.060362162 -0.0161031 TssA
SPAG8 0.01459712 0.059483616 0.043595364 -0.0158883 TssA
TRIM52 0.03793486 0.074715717 0.058972862 -0.0157429 TssA
CTTNBP2NL 0.02102139 0.063446364 0.047770009 -0.0156764 TssAFlnk
FEN1 0.0132314 0.060697192 0.04570941 -0.0149878 TssA
ARAP1 0.03119021 0.068697585 0.053845278 -0.0148523 TssAFlnk
P2RY2 0.02193957 0.061330251 0.047030434 -0.0142998 TssAFlnk
LYST 0.03838011 0.064404389 0.050144081 -0.0142603 TssAFlnk
CREG1 0.01089236 0.070886466 0.056716703 -0.0141698 TssAFlnk
TRNAU1AP 0.03449519 0.084005947 0.069869466 -0.0141365 TssA
TCEB1P 0.01030404 0.886625633 0.872700806 -0.0139248 TxWk
CENPO 0.02035497 0.069786227 0.055879655 -0.0139066 TssAFlnk
MRPS14 0.00896861 0.087784565 0.073952843 -0.0138317 TssA
ZNF684 0.01498347 0.067587301 0.053842915 -0.0137444 TssA
SIRT5 0.02632483 0.074327427 0.060759822 -0.0135676 TssA
GRM2 0.02441085 0.804866927 0.791359337 -0.0135076 ReprPCWk
CIRH1A 0.03804824 0.045322307 0.031825228 -0.0134971 TssA
EIF3K 0.0251968 0.075008268 0.061525977 -0.0134823 TssA
C17orf80 0.01993751 0.071518723 0.058163208 -0.0133555 TssA
ZNF426 0.04555207 0.054427399 0.041114844 -0.0133126 TssA
TNKS 0.01138186 0.085266021 0.072143523 -0.0131225 TssAFlnk
IGFBP3 0.00533531 0.067707863 0.054606815 -0.013101 TssAFlnk
NAT8L 0.04089995 0.090589777 0.077927318 -0.0126625 ReprPCWk
FAM73B 0.03541064 0.060473307 0.047865617 -0.0126077 TssA
WDR17 0.0177667 0.052012355 0.039627899 -0.0123845 BivFlnk
PTER 0.02102671 0.057654329 0.045273243 -0.0123811 TssA
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MORN4 0.02137065 0.115248052 0.10287719 -0.0123709 TssA
PIAS1 0.00355468 0.048704108 0.036451978 -0.0122521 TssA
CCDC12 0.00514437 0.080636414 0.06845807 -0.0121783 TssA
TOMM20L 0.02645209 0.109360371 0.097184846 -0.0121755 TssAFlnk
CDK12 0.04639584 0.068108284 0.055955295 -0.012153 TssA
AVEN 0.01015559 0.060997665 0.048912241 -0.0120854 TssA
IGFBP3 0.01315997 0.114753625 0.102682648 -0.012071 TssAFlnk
AGPAT1 0.01362337 0.046738134 0.034692025 -0.0120461 TssA
USE1 0.01127456 0.041426146 0.029404013 -0.0120221 TssA
ITSN2 0.0007257 0.052831452 0.040918851 -0.0119126 TssA
C11orf24 0.01139479 0.076842742 0.065003778 -0.011839 TssAFlnk
MRPL12 0.00120779 0.044008316 0.032608585 -0.0113997 TssA
BET1 0.03794652 0.07144943 0.060133976 -0.0113155 TssA
MTFR1 0.00670409 0.050829184 0.039594549 -0.0112346 TssAFlnk
CCNO 0.01057098 0.053418187 0.042223105 -0.0111951 TssAFlnk
RAMP2 0.02047989 0.069592117 0.058401215 -0.0111909 TssBiv
RGS4 0.02285144 0.058440985 0.047359888 -0.0110811 TssA
UGDH 0.01736461 0.053011505 0.042233866 -0.0107776 TssA
SIRPA 0.04905657 0.05439883 0.04384717 -0.0105517 TssAFlnk
SMEK1 0.02376752 0.050496735 0.039990431 -0.0105063 TssAFlnk
PKIG 0.02931239 0.053280498 0.042794386 -0.0104861 TssA
ARHGAP11A 0.01443503 0.044333835 0.033855903 -0.0104779 TssA
PCYOX1L 0.01033408 0.061857186 0.051443557 -0.0104136 TssAFlnk
FKBP7 0.0358445 0.059603281 0.049262723 -0.0103406 TssA
ITPR2 0.00052306 0.043768212 0.033483095 -0.0102851 TssA
RASGRP2 0.02227512 0.052620769 0.042389651 -0.0102311 BivFlnk
ICA1 0.03534593 0.076066103 0.065863172 -0.0102029 TssBiv
C19orf22 0.00239819 0.037354364 0.027234903 -0.0101195 TssA
EXOC7 0.03377622 0.051401987 0.041369025 -0.010033 TssAFlnk
PROS1 0.0009823 0.041866449 0.031905781 -0.0099607 TssAFlnk
KDELC1 0.02208017 0.034077508 0.024234884 -0.0098426 TssA
C6orf208 0.00479972 0.06040128 0.05074725 -0.009654 TssAFlnk
ATXN7 0.04937938 0.047494644 0.037853918 -0.0096407 TssAFlnk
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AP3D1 0.00524164 0.048159624 0.038528961 -0.0096307 TssA
C17orf79 0.04502456 0.043775647 0.034335881 -0.0094398 TssAFlnk
THAP7 0.00088371 0.036083783 0.026646513 -0.0094373 TssA
DUSP11 0.0404954 0.056499579 0.047084587 -0.009415 TssA
ARMC4 0.01009932 0.056141836 0.046740352 -0.0094015 TssA
ARHGEF10L 0.00126943 0.041833181 0.03245695 -0.0093762 TssA
STK17A 0.00374104 0.042109881 0.032798714 -0.0093112 TssA
STRBP 0.00100071 0.033882343 0.024694862 -0.0091875 TssBiv
C17orf71 0.0161824 0.045126476 0.035970345 -0.0091561 TssA
KRIT1 0.00693537 0.046675824 0.037755767 -0.0089201 TssA
LPPR2 0.00109955 0.031538833 0.02263574 -0.0089031 TssA
SGK3 0.04364248 0.054258537 0.045389527 -0.008869 TssAFlnk
SMARCAL1 0.01388802 0.948274424 0.939438161 -0.0088363 TxWk
H3F3B 0.01309699 0.034622164 0.025840709 -0.0087815 TssA
VAX2 0.0148674 0.054230668 0.045457854 -0.0087728 TssBiv
NPAS1 0.03995326 0.067080752 0.058338268 -0.0087425 TssA
SOX2 0.01779516 0.04084208 0.032116939 -0.0087251 TssBiv
VWC2 0.01692226 0.069296446 0.060582251 -0.0087142 ReprPC
NFKB2 0.00312917 0.056645442 0.047938927 -0.0087065 TssA
GMNN 0.04735248 0.058779983 0.050103873 -0.0086761 TssAFlnk
RPS3 0.01956712 0.03925675 0.030604353 -0.0086524 TssA
LASS1 0.03598191 0.066959587 0.058329739 -0.0086298 TssA
GTF2B 0.01908092 0.045865191 0.037292047 -0.0085731 TssA
TUSC4 0.02625848 0.058748009 0.050217253 -0.0085308 TssA
UBQLN1 0.01920543 0.03219752 0.023676935 -0.0085206 TssA
IL2RB 0.03587898 0.947858472 0.93933824 -0.0085202 ReprPCWk
GALNT10 0.04841726 0.05409313 0.045603731 -0.0084894 TssA
STK3 0.00553781 0.060450066 0.052026068 -0.008424 TssA
USP32 0.02363012 0.063247487 0.054846043 -0.0084014 TssA
TRAF3 0.02601893 0.045850719 0.03754884 -0.0083019 TssA
SERTAD1 0.04282193 0.035015134 0.026726167 -0.008289 TssA
BCCIP 0.04669591 0.040458306 0.032172298 -0.008286 TssA
FCF1 0.01193274 0.055425143 0.047139287 -0.0082859 TssA
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DHRS7 0.00800592 0.041152685 0.032874208 -0.0082785 TssA
PLEKHA1 0.00061521 0.047796199 0.03952023 -0.008276 TssAFlnk
IL6ST 0.04540702 0.047725303 0.039455359 -0.0082699 TssA
KLF16 0.00227269 0.051629374 0.043367391 -0.008262 TssA
MLLT1 0.03897436 0.052100132 0.043838649 -0.0082615 TssA
ARL6IP1 0.04564164 0.046699176 0.038470366 -0.0082288 TssAFlnk
KRAS 0.00988549 0.036345936 0.028227001 -0.0081189 TssA
DEDD2 0.01413059 0.045526981 0.03743779 -0.0080892 TssA
HOXB7 0.01070765 0.045636455 0.037630793 -0.0080057 TssAFlnk
USP49 0.00582399 0.054121718 0.046120445 -0.0080013 TssA
TERF2 0.01469355 0.034359892 0.026364124 -0.0079958 TssA
VPS13A 0.00659205 0.031647725 0.023706753 -0.007941 TssA
KCNT2 0.01553165 0.049057339 0.041117341 -0.00794 TssA
GCAT 0.03620264 0.062470726 0.05453672 -0.007934 TssAFlnk
NUP35 0.0254194 0.060064311 0.052214267 -0.00785 TssA
AGL 0.02027 0.050457438 0.042611496 -0.0078459 TssA
SMAD7 0.0005026 0.029653223 0.021852678 -0.0078005 TssA
HIST1H2AH 0.00808432 0.046055959 0.038273324 -0.0077826 TssA
ITSN1 0.0238299 0.0441831 0.036444203 -0.0077389 TssA
ALKBH6 0.01782156 0.046559816 0.038832702 -0.0077271 TssA
AP1AR 0.00326201 0.036492837 0.028769461 -0.0077234 TssA
CCBL1 0.03751351 0.039116261 0.031449002 -0.0076673 TssA
CDK5RAP2 0.02986907 0.035277045 0.027678795 -0.0075982 TssAFlnk
CUL3 0.04388957 0.0656926 0.058124414 -0.0075682 TssAFlnk
ZNF643 0.04162479 0.046473679 0.038915015 -0.0075587 TssA
INTS4 0.00407534 0.040608153 0.033081192 -0.007527 TssA
PAK4 0.04062459 0.042058284 0.034597568 -0.0074607 TssA
CDC42EP4 0.02315251 0.030428929 0.02297559 -0.0074533 TssA
SMU1 0.04728724 0.048591359 0.041146949 -0.0074444 TssA
U2AF1 0.01377259 0.039058326 0.031662282 -0.007396 TssAFlnk
CHPT1 0.03929987 0.070358187 0.062976329 -0.0073819 TssAFlnk
TFG 0.01600953 0.046099631 0.038740256 -0.0073594 TssA
KIF17 0.00963256 0.023078774 0.015760701 -0.0073181 TssA
Page 71 of 135
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
SLC31A2 0.00393025 0.036366321 0.029096062 -0.0072703 TssA
PCDH1 0.02513833 0.046705451 0.039438951 -0.0072665 TssA
DDT 0.03811795 0.035823731 0.028576199 -0.0072475 Quies
TTK 0.04646597 0.04869781 0.041591245 -0.0071066 TssA
KDM3A 0.02266132 0.048086996 0.040982033 -0.007105 TssA
LGI3 0.04265164 0.049807164 0.042715149 -0.007092 BivFlnk
FLRT2 0.00199561 0.026195755 0.019122182 -0.0070736 TssA
DNAJB4 0.03251859 0.056508587 0.049469755 -0.0070388 TssA
ATP2A3 0.00776928 0.044936381 0.037955749 -0.0069806 BivFlnk
PTPLA 0.04452423 0.066879277 0.059931982 -0.0069473 TssAFlnk
NDUFC2 0.01795521 0.050447502 0.04350535 -0.0069422 TssA
PER1 0.02104779 0.033892004 0.027031512 -0.0068605 TssA
MYH10 0.03778243 0.041882373 0.035028865 -0.0068535 TssA
C15orf57 0.03922952 0.054039371 0.047264384 -0.006775 TssA
C4orf22 0.04745935 0.033052354 0.026282654 -0.0067697 TssA
FOXA3 0.00848282 0.03672584 0.029979165 -0.0067467 TssBiv
WNT2B 0.02359799 0.031868981 0.025173465 -0.0066955 TssAFlnk
DCBLD2 0.0269049 0.03629647 0.029604015 -0.0066925 TssA
EPHB1 0.0148784 0.029825086 0.023135839 -0.0066892 TssAFlnk
LETM2 0.00031652 0.040410532 0.033733035 -0.0066775 TssA
PRR16 0.0370732 0.038023884 0.031347138 -0.0066767 TssA
PFKP 0.02966705 0.044756992 0.038090524 -0.0066665 TssA
GLUL 0.03235519 0.033324048 0.026704556 -0.0066195 TssA
LSS 0.02605935 0.031966578 0.025366591 -0.0066 TssA
BMP2K 0.03128836 0.043393063 0.036796414 -0.0065966 TssA
NDUFB8 0.01228649 0.057234369 0.050643589 -0.0065908 TssA
MLH3 0.00328819 0.047078832 0.040493357 -0.0065855 TssAFlnk
ADAP2 0.03424522 0.048030029 0.04144584 -0.0065842 TssBiv
RAB8B 0.00060179 0.031104496 0.024539027 -0.0065655 TssA
MRC2 0.00273905 0.042787124 0.036234947 -0.0065522 TssA
ARHGEF17 0.02277319 0.03356517 0.027015347 -0.0065498 TssA
FN1 0.03448488 0.039985565 0.033477844 -0.0065077 TxFlnk
CREB3 0.04158884 0.031667577 0.025162 -0.0065056 TssA
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RNF19B 0.02890762 0.064596163 0.058092587 -0.0065036 TssA
RETSAT 0.01066965 0.037967675 0.031476318 -0.0064914 TssAFlnk
DNAJC18 0.02152515 0.036644171 0.030191778 -0.0064524 TssA
RNGTT 0.04531341 0.044450894 0.038018697 -0.0064322 TssA
ZC3H15 0.04546441 0.038939013 0.03251481 -0.0064242 TssA
SMOC2 0.03317958 0.048631675 0.042218451 -0.0064132 BivFlnk
PEX5 0.01092912 0.03602895 0.029622498 -0.0064065 TssA
BOP1 0.03290605 0.042911297 0.036521153 -0.0063901 TssA
LHFP 0.00073665 0.032626304 0.026259935 -0.0063664 TssA
EEF2 0.02866073 0.046690131 0.040331737 -0.0063584 TssAFlnk
STK36 0.03508778 0.046235218 0.039892968 -0.0063422 TssA
FAM70B 0.00896003 0.032153234 0.025831149 -0.0063221 TssAFlnk
SFRS14 0.03721516 0.043964896 0.03764365 -0.0063212 TssAFlnk
MCM7 0.04014743 0.045521396 0.039217684 -0.0063037 TssA
C10orf2 0.03806278 0.036915608 0.03061285 -0.0063028 TssA
TIGD3 0.0427174 0.030368287 0.024070534 -0.0062978 TssAFlnk
PTPN23 0.00725224 0.034041976 0.027762767 -0.0062792 TssA
NINJ1 0.0472017 0.033151483 0.026929698 -0.0062218 TssAFlnk
UTP3 0.00939888 0.038936324 0.032714845 -0.0062215 TssA
NUP54 0.01480584 0.031004631 0.024836109 -0.0061685 TssA
REXO2 0.01546754 0.04342376 0.037297292 -0.0061265 TssAFlnk
MATR3 0.01068208 0.034828753 0.028703622 -0.0061251 TssAFlnk
LOXL2 0.02245811 0.031658309 0.025549177 -0.0061091 TssA
TUBA1B 0.00358028 0.036268205 0.030177061 -0.0060911 TssAFlnk
CWF19L1 0.01246995 0.047344703 0.041277455 -0.0060672 TssA
TMEM199 0.04972813 0.048803432 0.042744418 -0.006059 TssA
SF3A3 0.02993303 0.02993803 0.023890539 -0.0060475 TssA
RPS27A 0.00100538 0.035633462 0.029611451 -0.006022 TssA
WDSUB1 0.02107152 0.031354156 0.025349 -0.0060052 TssA
BBS4 0.0182609 0.053419114 0.047435334 -0.0059838 TssA
CNDP2 0.03495629 0.062854994 0.056897492 -0.0059575 TssA
DPP3 0.00528205 0.025895318 0.019951473 -0.0059438 TssA
ZNF660 0.01648934 0.031827414 0.025885318 -0.0059421 TssAFlnk
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ULK1 0.00326767 0.026577397 0.020641378 -0.005936 TssA
PSMG1 0.01365757 0.029686637 0.023756551 -0.0059301 TssA
NUDT22 0.01549225 0.035585074 0.029682654 -0.0059024 TssA
GAS6 0.01685254 0.032213199 0.026317906 -0.0058953 TssA
ST3GAL5 0.04150829 0.051416702 0.045528019 -0.0058887 TssA
NUDCD3 0.0150433 0.039404708 0.033517247 -0.0058875 TssA
CYBASC3 0.02461417 0.045603319 0.039730212 -0.0058731 TssA
AKR1B1 0.04549819 0.029444518 0.023581247 -0.0058633 TssA
MEN1 0.02410109 0.043853914 0.038022986 -0.0058309 TssA
ARL8A 0.02869655 0.043138836 0.037325448 -0.0058134 TssAFlnk
ZNF276 0.00909222 0.035009906 0.029197936 -0.005812 TssA
AHCY 0.0363606 0.031200935 0.025393757 -0.0058072 TssA
FBXL3 0.03831974 0.027499836 0.021722499 -0.0057773 TssA
STAM2 0.03136427 0.036307626 0.030534372 -0.0057733 TssA
FBXW7 0.02734912 0.044270636 0.03852394 -0.0057467 TssA
TWSG1 0.00761005 0.022498632 0.016775025 -0.0057236 TssA
ETHE1 0.03137927 0.033797762 0.028114872 -0.0056829 TssA
STOM 0.00102201 0.029165688 0.023483217 -0.0056825 TssA
BAT5 0.0291427 0.040582538 0.03490279 -0.0056797 TssA
MCL1 0.01655259 0.040500803 0.034852362 -0.0056484 TssA
STK10 0.04834753 0.033978691 0.028351045 -0.0056276 TssA
FAR1 0.02936404 0.043344516 0.037728827 -0.0056157 TssA
RRBP1 0.03399537 0.028579976 0.02298511 -0.0055949 TssA
PLK2 0.04484715 0.034875861 0.029289226 -0.0055866 TssA
ERBB3 0.02285439 0.047303575 0.041758356 -0.0055452 TssAFlnk
RAB11FIP5 0.00332487 0.040105651 0.034606307 -0.0054993 TssAFlnk
NAALAD2 0.01189535 0.044212908 0.038720793 -0.0054921 TssA
TP53INP2 0.01261778 0.024645596 0.019155823 -0.0054898 TssA
PMS2L3 0.01074602 0.03455385 0.029118371 -0.0054355 TssA
ADAMTS1 0.04904234 0.050295089 0.044883048 -0.005412 TssA
GLYR1 0.04709291 0.029560909 0.024149022 -0.0054119 TssA
CCAR1 0.00241788 0.038014532 0.03260791 -0.0054066 TssA
CANT1 0.04274823 0.034954193 0.029557009 -0.0053972 TssAFlnk
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GABRA2 0.03699709 0.03111229 0.025749594 -0.0053627 ReprPC
TTC12 0.01301609 0.023072572 0.017715076 -0.0053575 TssA
ZBTB7A 0.02050866 0.042146759 0.036803402 -0.0053434 TssA
SGTB 0.00077659 0.03942572 0.034086143 -0.0053396 TssA
LITAF 0.04648308 0.051953222 0.046675193 -0.005278 TssA
C7orf25 0.0269682 0.037988643 0.032726966 -0.0052617 TssA
SLCO4A1 0.01757595 0.038084745 0.032833034 -0.0052517 ReprPC
TMF1 0.00671608 0.027798594 0.022568218 -0.0052304 TssA
MAP4K5 0.02883626 0.029934501 0.024704909 -0.0052296 TssAFlnk
EMP2 0.00624884 0.027349989 0.022160558 -0.0051894 TssA
ZBTB5 0.03392047 0.048405136 0.0432341 -0.005171 TssA
CDS1 0.00811835 0.032405454 0.027299728 -0.0051057 BivFlnk
FPGS 0.00229857 0.029778548 0.024699525 -0.005079 TssAFlnk
SERF2 0.00814691 0.023377113 0.018315587 -0.0050615 TssA
VPS45 0.01640619 0.035861665 0.030800555 -0.0050611 TssA
TARBP1 0.0435149 0.025222101 0.02016585 -0.0050563 TssA
MC1R 0.02320604 0.033590337 0.028567752 -0.0050226 TssAFlnk
NEIL3 0.01888028 0.031200387 0.026225273 -0.0049751 TssA
EPSTI1 0.00701157 0.029503391 0.024547546 -0.0049558 TssAFlnk
RDX 0.02380704 0.042601302 0.037647363 -0.0049539 TssA
SPATA13 0.03719954 0.031040205 0.026103613 -0.0049366 TssA
RFC1 0.04848803 0.047889548 0.04295935 -0.0049302 TssAFlnk
GPR89B 0.02137601 0.03223586 0.027325306 -0.0049106 TssA
FECH 0.00973006 0.03206643 0.027175104 -0.0048913 TssA
CDC26 0.03723455 0.042397754 0.037509281 -0.0048885 TssA
CUX1 0.01414414 0.039064938 0.034180442 -0.0048845 TssAFlnk
MFN1 0.01668114 0.029157108 0.024285306 -0.0048718 TssA
ZNF671 0.01395794 0.044698792 0.039855141 -0.0048437 TssA
TRNT1 0.03320163 0.033112851 0.028289192 -0.0048237 TssA
CBL 0.00283196 0.028674703 0.023867995 -0.0048067 TssA
FAM179B 0.03438575 0.028397988 0.023592436 -0.0048056 TssA
NTN4 0.03333845 0.028466065 0.023679604 -0.0047865 TssA
LASP1 0.03594794 0.027527147 0.02274656 -0.0047806 TssA
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MAD2L2 0.00923308 0.029745355 0.024979685 -0.0047657 TssAFlnk
PPP1R14C 0.01121106 0.031878957 0.027152898 -0.0047261 TssA
H6PD 0.04374972 0.026859752 0.022141668 -0.0047181 TssAFlnk
DSTN 0.0018111 0.029776866 0.025107676 -0.0046692 TssA
PPME1 0.03481161 0.035156701 0.030489916 -0.0046668 TssA
MAN1B1 0.00443746 0.021132082 0.016495719 -0.0046364 TssA
CENPM 0.02375524 0.02888732 0.024251195 -0.0046361 TssA
NFYB 0.03665324 0.028489059 0.023876936 -0.0046121 TssA
RAB20 0.01294929 0.043589041 0.038988874 -0.0046002 TssA
CAPNS1 0.03470187 0.022756023 0.018172161 -0.0045839 TssA
USP5 0.00899156 0.037896448 0.033347318 -0.0045491 TssA
LEO1 0.01888537 0.027399025 0.022896731 -0.0045023 TssA
CCNYL1 0.02260043 0.030267574 0.025776493 -0.0044911 TssA
NQO2 0.02546066 0.032966867 0.028515429 -0.0044514 TssAFlnk
ERCC2 0.04136944 0.048266662 0.043831433 -0.0044352 TssA
HINFP 0.00797935 0.02820367 0.023772577 -0.0044311 TssA
FOS 0.02099371 0.033525014 0.029113153 -0.0044119 TssA
RBM19 0.01434966 0.03110754 0.026715434 -0.0043921 TssA
C18orf54 0.00402347 0.024806613 0.020458184 -0.0043484 TssA
DCAF4 0.03007014 0.03642753 0.032080046 -0.0043475 TssA
TRAF7 0.0484326 0.040084122 0.035765608 -0.0043185 TssA
LRRC59 0.0405282 0.03056687 0.026260483 -0.0043064 TssA
PRRG4 0.04203942 0.033617409 0.029312082 -0.0043053 TssAFlnk
ENTPD6 0.03877374 0.022667136 0.018398361 -0.0042688 TssA
ZSCAN22 0.01559393 0.021025168 0.016781798 -0.0042434 TssA
SNAI1 0.02292081 0.030572682 0.026367648 -0.004205 TssA
TMEM159 0.01386308 0.035893077 0.031707856 -0.0041852 TssAFlnk
PTGR2 0.03003093 0.031356447 0.027215262 -0.0041412 TssA
TMEM38B 0.03764373 0.033724022 0.029586247 -0.0041378 TssA
NIPSNAP3B 0.0122543 0.027988287 0.023857908 -0.0041304 TssA
DIABLO 0.04397074 0.025067625 0.02094181 -0.0041258 TssA
AQP6 0.03628381 0.029606234 0.025485378 -0.0041209 TssAFlnk
USP13 0.00902235 0.025854934 0.02174893 -0.004106 TssA
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SSSCA1 0.01068533 0.028406971 0.02432964 -0.0040773 TssA
SMPD1 0.0118565 0.021748686 0.017675199 -0.0040735 TssAFlnk
EPHB3 0.00916313 0.031185778 0.027112542 -0.0040732 TssAFlnk
BMPR1A 0.01521057 0.028084917 0.024048654 -0.0040363 TssA
POLE 0.04889595 0.026579854 0.022576022 -0.0040038 TssA
TSSK3 0.02752596 0.026057673 0.022072311 -0.0039854 TssAFlnk
CABC1 0.02954861 0.02316912 0.019225694 -0.0039434 TssA
RAC1 0.04915629 0.028953652 0.025042791 -0.0039109 TssA
GNPTAB 0.04334063 0.024811906 0.020907328 -0.0039046 TssA
BRI3 0.01304725 0.023208101 0.019316754 -0.0038913 TssA
SLC35E2 0.04553249 0.033369272 0.029522135 -0.0038471 TssA
CYP26A1 0.03764375 0.03380063 0.029971452 -0.0038292 BivFlnk
TMEM117 0.02586041 0.030684926 0.026930256 -0.0037547 TssA
CCNT1 0.02605111 0.030583614 0.026892184 -0.0036914 TssA
KDM5B 0.02741302 0.021445782 0.01775871 -0.0036871 TssA
ROCK1 0.04257202 0.019868681 0.016227997 -0.0036407 TssA
B3GAT1 0.03037106 0.021145565 0.017530296 -0.0036153 ReprPCWk
MEIS1 0.04891204 0.024884873 0.021277772 -0.0036071 TssA
ETF1 0.02014838 0.023614922 0.020019365 -0.0035956 TssA
NTNG1 0.018203 0.02852333 0.02493563 -0.0035877 BivFlnk
RHPN2 0.02311493 0.027222221 0.023648314 -0.0035739 TssBiv
ZNF14 0.04370669 0.025965324 0.022403379 -0.0035619 TssA
SNX5 0.03034468 0.027689118 0.024150051 -0.0035391 TssA
B3GALNT1 0.0315624 0.029384634 0.025865096 -0.0035195 TssA
NSUN4 0.02039014 0.022290656 0.01877373 -0.0035169 TssA
GNL1 0.04687876 0.020808035 0.017338077 -0.00347 TssA
NSUN5 0.03684782 0.03568951 0.03225072 -0.0034388 TssA
ZNF295 0.01351433 0.026961538 0.023528252 -0.0034333 TssA
HIC2 0.03786639 0.019588719 0.016157559 -0.0034312 Quies
PDIA2 0.04693515 0.02709105 0.023678939 -0.0034121 ReprPCWk
ASCC3 0.04767309 0.018934135 0.015539075 -0.0033951 TssA
ADARB1 0.03262539 0.027979275 0.024623745 -0.0033555 TssA
MED8 0.03505012 0.021291135 0.017974585 -0.0033165 TssA
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TM9SF1 0.04082707 0.024421242 0.021175558 -0.0032457 TssA
PRPF38B 0.00551465 0.01854962 0.015305946 -0.0032437 TssA
CA11 0.04509736 0.026005145 0.022817215 -0.0031879 TssAFlnk
LRRC61 0.04574681 0.032986111 0.029806612 -0.0031795 TssAFlnk
CDKN1C 0.02679909 0.02542377 0.022245944 -0.0031778 TssA
STAM 0.0387211 0.0267589 0.023613007 -0.0031459 TssA
GSC 0.01332164 0.025147409 0.022025225 -0.0031222 ReprPC
CEBPA 0.02221256 0.019262368 0.016145881 -0.0031165 TssA
PGM2 0.04123314 0.026056363 0.023050605 -0.0030058 TssA
DSP 0.02682411 0.020630535 0.017625438 -0.0030051 TssA
DMRTA1 0.04076872 0.019750532 0.016782445 -0.0029681 TssA
PDIA6 0.03475949 0.02245816 0.019490628 -0.0029675 TssA
COPB2 0.04184806 0.027457997 0.024524746 -0.0029333 TssA
CENPJ 0.00981501 0.019545873 0.016694804 -0.0028511 TssA
SETD7 0.03375734 0.029944901 0.027105663 -0.0028392 TssA
ZBTB48 0.03920383 0.020995358 0.018179259 -0.0028161 TssA
POLR2J2 0.0492179 0.021502514 0.01872032 -0.0027822 TssA
TBL3 0.04156133 0.026796379 0.024044247 -0.0027521 TssA
ARRDC2 0.02379111 0.014626499 0.011918685 -0.0027078 TssA
ADAMTS9 0.04393183 0.030832121 0.028160834 -0.0026713 TssAFlnk
SLC2A13 0.02550401 0.024561559 0.021906098 -0.0026555 TssA
ABCC5 0.04430486 0.026141737 0.023559563 -0.0025822 TssA
C2orf42 0.03119265 0.02589365 0.023365256 -0.0025284 TssA
EPHB6 0.04465606 0.024686511 0.022177286 -0.0025092 TssAFlnk
TRPA1 0.04110428 0.031612448 0.029232611 -0.0023798 TssBiv
ACSF2 0.04273206 0.021248041 0.019002209 -0.0022458 TssA
B9D2 0.03150836 0.042199432 0.040291668 -0.0019078 TssAFlnk
CDK2AP1 0.04972714 0.024136821 0.02239486 -0.001742 TssA
DML: differentially methylated loci; mtDNA: mitochondrial DNA; TssA: active transcription start site; TssAFlnk: transcription at gene 5´and 3; TxFlnk: strong transcription; TxWk: weak 
transcription; Enh: enhancer; TssBiv: bivalent/poised transcription start site; BivFlnk: bivalent enhancer; ReprPC: Repressed PolyComb; ReprPCWk: weak repressed PolyComb; Quies: 
quiescent/low; adj. p-value: adjusted p-values calculated by Bonferroni´s method
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S2 table. Differentially expressed genes between mtDNA haplogroups J and H sorted by decreased logFc 
Increased expression in mtDNA 
haplogroup H in relation to J
Increased expression in mtDNA 
haplogroup J in relation to H
GENE 
SYMBOL adj. p-value logFc
GENE 
SYMBOL adj. p-value logFc
FOSB 0.03998083 3.478529174 SCN5A 0.000907108 7.013483898
TAS2R31 0.030067242 3.433978661 ATP2C2 0.000839286 6.92543196
TBC1D3L 0.029154877 3.413960418 MROH2A 0.001270518 6.835315507
CTGF 0.022397751 3.302501323 TLX1 0.000839286 6.807543643
AC005324.8 0.035007673 3.146840916 TLL1 0.001116654 6.580521745
OSCAR 0.029386385 3.145865483 STAB2 0.011137621 6.541071584
SOD3 0.034634315 3.135166024 PTPRT 0.003078355 6.495487326
GPX3 0.048592903 2.964838113 EYA2 0.001098212 6.486761238
RSC1A1 0.032120977 2.938135424 SPTA1 0.000907108 6.436467797
CEBPD 0.045865205 2.886009883 MUC16 0.005056309 6.428173657
ZFP36 0.046181364 2.820222039 AQP12B 0.000839286 6.41596414
CST3 0.017748612 2.795276953 STXBP5L 0.000839286 6.365605044
VIM 0.03352273 2.71725799 FBN3 0.00131709 6.357744641
DUSP1 0.048530058 2.694311542 ADGRL3 0.001348285 6.21781099
KLF2 0.02792498 2.51153556 DNAH8 0.001804147 6.207393936
STC2 0.027323034 2.472495807 LRRC71 0.001098212 6.204126262
NAMPT 0.022275795 2.384588147 SLC22A8 0.001098212 6.203149651
ERRFI1 0.045800126 2.384056558 VWA5B2 0.002020397 6.176655969
ZNF385B 0.006592803 2.315358783 EPS8L3 0.000907108 6.163148974
ZBTB16 0.013349591 2.313422528 SH3GL2 0.003022595 6.141789901
SOX9 0.02551613 2.294780119 OTOG 0.001712362 6.094021175
SERPING1 0.04315234 2.284860228 PRSS36 0.001109021 6.012235637
CSPG4 0.037835852 2.284441883 GPR158 0.000907108 5.990188936
SRRM2 0.028088316 2.220781427 PTPRO 0.001257521 5.990133673
LENG8 0.028081249 2.21736219 KCNQ1 0.000839286 5.987750573
KLF4 0.024681415 2.201584151 MUC3A 0.003268599 5.963205763
MTSS1L 0.034374305 2.189602608 EDN2 0.001098212 5.949913921
PRR4 0.011261504 2.175892069 SORCS1 0.001270518 5.937803159
FKBP5 0.036649291 2.17347459 ELAVL4 0.001098212 5.909721528
MICALCL 0.041270174 2.141271921 MEST 0.001098212 5.905897735
TSC22D1 0.046193465 2.133168902 KCNJ1 0.001391706 5.898983574
SLC19A2 0.021724556 2.119630562 TOX3 0.001098212 5.894297671
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SOCS4 0.017151111 2.11566791 USH2A 0.002277115 5.893225024
ZFHX3 0.040404538 2.09375996 HKDC1 0.002518505 5.863126774
PAPSS2 0.034117483 2.088521189 DISP3 0.001559518 5.861215328
TNFRSF11B 0.011121593 2.077609729 ITIH3 0.003114265 5.845283181
PPP1R3C 0.049568011 2.07200409 TTLL10 0.000943693 5.838750668
KLF5 0.021355725 2.041792653 COL4A4 0.001098212 5.816333118
PLPP1 0.047389189 2.017130746 IKZF1 0.001098212 5.814601364
GOLGA6L9 0.021737482 2.014726622 XKR7 0.001098212 5.801344002
FOSL2 0.031989532 1.998881893 TPO 0.001098212 5.790175976
SLC7A2 0.008417687 1.985231021 ARPP21 0.001098212 5.776906425
HMGA1 0.037554223 1.980684862 CACNA1S 0.001413445 5.762072084
HS3ST3A1 0.006067936 1.968362351 MYCL 0.002266763 5.760103262
ARID5B 0.018305733 1.949388006 ANO2 0.001914691 5.755397611
ABCA1 0.009696061 1.941933537 FHOD3 0.001257521 5.746752843
SRSF5 0.045454203 1.9408897 RYR2 0.008615202 5.732012815
RAB11FIP2 0.020822913 1.939394943 ANKRD33 0.000907108 5.723579887
AKT3 0.037611537 1.90659422 SCN10A 0.001098212 5.700288947
SHISA3 0.016377123 1.902166685 CGB2 0.00130328 5.691281162
DUSP16 0.031597682 1.893946756 MUC5AC 0.001098212 5.690252552
TOB2 0.037392526 1.892816805 CARD11 0.002678295 5.669572151
ELL2 0.020397212 1.8923844 RBM46 0.001098212 5.667370233
SLC39A14 0.046441546 1.89169209 DSCAM 0.001109021 5.656574382
WISP2 0.014087449 1.878659613 PGLYRP2 0.001098212 5.654667668
ACADL 0.004484873 1.867341161 MYO18B 0.002485084 5.646195943
ITGA10 0.028950403 1.862692622 KLHDC7A 0.001098212 5.632384952
EMP1 0.046578837 1.84688413 CPNE4 0.001109021 5.628816231
H1F0 0.036909774 1.846262686 IGSF10 0.001559518 5.61629979
CEBPB 0.048623898 1.845665843 MYOCD 0.001947692 5.605083371
SH3D21 0.008936407 1.837263462 ATG9B 0.001098212 5.594357254
ZFP36L1 0.043458667 1.833313688 DLK1 0.001229282 5.584909702
CDKN1A 0.02008182 1.817895234 CCDC60 0.00130328 5.568481447
SNRNP70 0.046880583 1.816729129 TSHR 0.001758484 5.564440713
FAM46A 0.03998083 1.814847569 BPIFB2 0.001270518 5.560178442
GSN 0.008864848 1.809845795 CPLX2 0.001559518 5.559277409
CLVS2 0.022584239 1.805508567 SLC22A31 0.001098212 5.557378391
NFKBIZ 0.043501265 1.798394542 OTP 0.007927026 5.555020082
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ATP1A1 0.041075339 1.79565401 COL6A5 0.001391706 5.553811204
PABPC1 0.042108084 1.791731791 UGT1A6 0.001098212 5.545828256
NKD1 0.039979533 1.790454824 PRDM13 0.000907108 5.530035883
PRRC2C 0.035478324 1.750618498 ARSI 0.001109021 5.527793559
FBRSL1 0.02669223 1.749710391 PRAME 0.001302819 5.523334579
CRYAB 0.034746916 1.738410563 GABRA5 0.002032099 5.521544773
SLC4A7 0.04632898 1.732407949 CD5 0.001082995 5.52062372
TBX15 0.042179781 1.723108478 WNT7A 0.001098212 5.51876106
ATN1 0.048530058 1.717626837 UMOD 0.006706412 5.517084207
DPYSL3 0.018616571 1.714009514 COL17A1 0.009074467 5.516236177
YBX3 0.04659258 1.70980194 GRIN1 0.003752596 5.506969577
KCNMA1 0.009074467 1.709470427 GUCY1A2 0.001438966 5.506341893
FRY 0.018725777 1.705177172 LHFPL4 0.001109021 5.505618693
GYS1 0.033586464 1.700310959 SELE 0.000907108 5.484334655
SMC5 0.038305007 1.700005119 AVPR1B 0.001270518 5.480237831
MKLN1 0.010105218 1.695638592 PPP1R16B 0.002974993 5.478501242
COPA 0.02938624 1.69519667 CBX2 0.001435796 5.471724768
OSBPL5 0.028500286 1.690830271 COL4A3 0.004932911 5.470976562
MFGE8 0.038160661 1.687808442 MNX1 0.001109021 5.469018226
DDX17 0.043802168 1.682082518 MYH7 0.001573628 5.468696601
AQR 0.010855971 1.67512207 FAT3 0.002009628 5.463600407
ARGLU1 0.03924128 1.673381967 PCSK5 0.001988926 5.461837962
CTTNBP2 0.017669286 1.67228224 ZIC2 0.000907108 5.461679636
ATP1B3 0.030436004 1.671956703 KRT85 0.001098212 5.460585488
MBNL1 0.034513072 1.671047182 C11orf45 0.001257521 5.459700253
CMSS1 0.041270174 1.664385736 ASCL2 0.001800777 5.457901682
ZC3H12A 0.024307485 1.654344743 MEGF11 0.001944651 5.452960042
SEC61A1 0.035299897 1.648392184 CDH16 0.001270518 5.452019558
LY6G5B 0.042095207 1.647701576 SCRT2 0.001116654 5.445114091
BTG1 0.043631304 1.641753277 NKX6-3 0.001098212 5.428589292
GALNT15 0.028456481 1.639620047 RASGRF1 0.001891438 5.426706752
ITGA5 0.009561345 1.618680374 NTSR1 0.001098212 5.422381206
PCF11 0.035239517 1.599020604 SLC17A8 0.001098212 5.417028035
TUBB2A 0.017434885 1.598935827 VSIG2 0.001406187 5.399734315
PPP4R4 0.039175634 1.597620547 ZNF804B 0.003990498 5.390254468
LPGAT1 0.039785237 1.587260096 ADGRA1 0.001219685 5.387571245
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PTRF 0.043563428 1.570053296 ZDHHC22 0.002485084 5.375415922
SFMBT2 0.023888134 1.561073206 ABCC12 0.002277115 5.37479503
CBLB 0.027172148 1.558873369 GPR78 0.009191014 5.374700692
UBAP2L 0.03010129 1.55376185 AJAP1 0.005294101 5.36806154
HS3ST3B1 0.014901719 1.551197566 BCO1 0.001098212 5.366195792
NPIPB12 0.013187702 1.55069733 SLC34A1 0.005472473 5.357471603
AGL 0.04199409 1.54530122 COL22A1 0.008436918 5.34370788
PSME4 0.039175634 1.533322669 OR4N2 0.00188708 5.342978589
RBM39 0.040242695 1.522694065 TTC24 0.001109021 5.335314361
KANSL1L 0.01664201 1.520161847 TRPA1 0.002812669 5.33475588
SASH1 0.034442357 1.515697433 MS4A8 0.001348285 5.329867358
MKNK2 0.045144563 1.509504176 NKAIN1 0.007358983 5.329383222
C1orf21 0.015024385 1.507880862 THSD7B 0.008578961 5.325475691
TNS2 0.023765508 1.507128211 TMEFF2 0.006668101 5.323382497
HNRNPH1 0.038188232 1.507029985 ABCG2 0.002277115 5.321553395
MUC1 0.011724947 1.503560984 ROS1 0.008168973 5.315550986
CAPN2 0.018724393 1.501812146 MYH1 0.001098212 5.313077769
SRPK1 0.010855971 1.501768889 OGDHL 0.00188708 5.309913824
RAB1A 0.025169769 1.493796603 ALPL 0.001573628 5.309405525
HHAT 0.028964684 1.490448642 PLCB2 0.005582149 5.30045878
GPR89B 0.045988195 1.484942316 XIRP2 0.003752596 5.291442899
SLC25A37 0.044145576 1.48246372 HSPA12B 0.001886172 5.283838321
SLC26A2 0.046107085 1.480542175 DNAI2 0.00130328 5.282264712
NARS 0.026033484 1.479921423 KCNQ2 0.003752596 5.280295479
CBWD3 0.010515783 1.478980666 KCNK12 0.001863317 5.279779583
KANSL1 0.038148178 1.477613905 C8orf74 0.001555162 5.267997364
TPST1 0.017601263 1.476922949 CAMK1G 0.001098212 5.263883655
RAPGEF2 0.043830946 1.472600466 TMEM163 0.001257521 5.259440087
TMOD1 0.046251894 1.464385876 SLC1A7 0.001818536 5.257046561
SMURF1 0.048502959 1.463721187 THEG 0.001098212 5.256417983
ADPRHL1 0.046880583 1.461387426 RAX 0.009442815 5.247524297
SETD5 0.048623898 1.458453968 KCNH2 0.001270518 5.244943142
S100A6 0.039815078 1.45476238 NR1H4 0.001712362 5.240763395
RP11-514P8.6 0.017612896 1.453527944 FA2H 0.001825737 5.233055065
AKNA 0.024522563 1.453298677 PRR15 0.00130328 5.232716626
LPCAT3 0.008436918 1.451259797 SHISA6 0.001940993 5.23043764
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SEC23IP 0.020172069 1.447927806 LGI1 0.003707836 5.230187929
WDR60 0.034210304 1.447292211 NRAP 0.001219685 5.227836808
SFSWAP 0.038728497 1.446658532 PPP3R2 0.003614605 5.225960339
NEBL 0.022021837 1.442832684 ASB10 0.001109021 5.223528845
ERICH1 0.046251894 1.437600377 EGF 0.004700467 5.216490099
WSB1 0.021079584 1.433337717 GIMAP8 0.001385184 5.216133986
NUMBL 0.020822913 1.43219378 KLK1 0.001219685 5.214855317
SELENOP 0.019436198 1.429400576 DNAH17 0.007390988 5.209401581
KMT2A 0.028786629 1.426135804 CNTN4 0.001098212 5.200955627
MXI1 0.044448914 1.424607494 RBP3 0.001109021 5.200248582
SESN1 0.023865144 1.417337767 MYO7B 0.001257521 5.198492179
SYNJ1 0.030586183 1.414338036 CCDC178 0.001800777 5.196393486
ZNF282 0.042108084 1.414245552 FCGR3A 0.001825737 5.187457813
ATXN7 0.010581015 1.413626022 FNDC10 0.001859794 5.187121357
B4GALT7 0.034513072 1.401266629 USH1G 0.005715706 5.18702243
HIPK2 0.027228495 1.397781582 GVQW2 0.001555162 5.185690063
GABARAPL1 0.036683651 1.396450975 CYP4F2 0.00130328 5.18266146
GOLGB1 0.02925575 1.395399611 MYH6 0.00377093 5.17752967
GPT2 0.043364301 1.394086958 GALNTL6 0.001712362 5.175156815
SEC31A 0.043282116 1.392224013 SCNN1B 0.002277115 5.168810878
WDR43 0.037684342 1.380015361 BCL6B 0.007563643 5.165294812
ELL 0.013763511 1.379662858 TACR1 0.001573628 5.163199455
NPIPB3 0.014807355 1.377396933 MRGPRX1 0.001109021 5.15711248
IL6R 0.019482695 1.377378989 RP11-766F14.2 0.001712362 5.1539894
EWSR1 0.036649291 1.373661344 NPAS1 0.001624613 5.15193558
ZMYND8 0.042395106 1.372881422 PTPRQ 0.004737235 5.150898373
FBXO11 0.046828942 1.37098675 CARMIL2 0.021373617 5.149613712
PMP22 0.029523524 1.368771046 CACNG4 0.001098212 5.143706228
LRRFIP2 0.01925732 1.368447429 C10orf128 0.001947692 5.139009096
PRKAG2 0.03660632 1.367192346 SMTNL2 0.001863317 5.137361624
CNOT8 0.04711586 1.365657773 ASTN1 0.003977521 5.133676294
PRUNE2 0.028608073 1.363230658 CKMT1B 0.001300132 5.133044873
LUC7L2 0.024522563 1.362550973 SLC22A12 0.001465894 5.131289971
ZNF385A 0.035981192 1.362518701 ANO3 0.002509996 5.122855324
AASS 0.035638247 1.360782931 MUC5B 0.014849303 5.120429934
IQGAP1 0.019808902 1.354067604 IL17REL 0.003699197 5.118373456
Page 83 of 135
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
AHI1 0.043939761 1.350900157 MAJIN 0.002009628 5.112749804
LONRF1 0.018690312 1.349180732 POTEG 0.00261761 5.110763029
SAFB 0.025143726 1.347270209 PDGFB 0.004667322 5.1087567
MADD 0.012256362 1.345377011 SLC5A7 0.001825737 5.106875669
FNIP1 0.026033484 1.344677964 CDCA2 0.001881455 5.103804938
GLTSCR2 0.044050528 1.343545207 B3GNT6 0.001219685 5.102239664
MYO9B 0.030213196 1.340445176 IMPG1 0.007962204 5.101598766
GLIS3 0.008168973 1.340019341 BCL11B 0.001098212 5.098603291
COBLL1 0.03697718 1.336986579 CNTNAP2 0.011406446 5.097227682
AUTS2 0.044376925 1.335803006 GRB7 0.003752596 5.094853152
KDM7A 0.040242695 1.334845302 KDM4E 0.001435796 5.09398101
ZNF841 0.028653619 1.334729791 KCNH7 0.001859794 5.093665171
TNKS1BP1 0.025143726 1.333382673 USP17L2 0.005872829 5.092661037
TMEM106A 0.044712981 1.330116546 DMRTB1 0.001825737 5.087516315
MIB1 0.030029686 1.328852806 AMPD1 0.00445506 5.083897556
POFUT2 0.041266332 1.328481526 DTHD1 0.00322086 5.0791317
USP53 0.048919045 1.327993866 RHCG 0.001270518 5.078446182
SRSF11 0.026976422 1.326261782 KLHL33 0.00188708 5.071751905
PAN2 0.042226254 1.326084626 ABCG4 0.002277115 5.071667427
MTMR7 0.04199409 1.32139207 KLK3 0.00130328 5.069055784
CASC3 0.04383848 1.316491692 C6orf201 0.00377093 5.060434248
EIF4A3 0.03024687 1.315641659 SLC6A3 0.00261761 5.059097188
SNED1 0.042157355 1.315303994 GPR139 0.001914691 5.058902497
TCERG1 0.031597682 1.313865573 SCN3A 0.015754494 5.043319915
RBM28 0.042179781 1.306913702 CTB-133G6.1 0.002354053 5.040414761
IBTK 0.041224353 1.303479262 MYT1L 0.000907108 5.038800135
SORBS3 0.04383848 1.303217251 SLA 0.008665547 5.035289071
EMSY 0.020822913 1.299036226 CFAP100 0.011613548 5.033811227
BDH1 0.045814496 1.286420902 C8B 0.00361749 5.033136283
GORAB 0.030029472 1.286136919 PCSK9 0.002233362 5.032530313
MALT1 0.028116131 1.281462211 CHRNG 0.001863317 5.021267914
TNIP1 0.018978261 1.278373938 CADPS 0.001270518 5.019754837
ANKRD28 0.03143521 1.278022235 MCHR1 0.003719784 5.019312906
PABPN1 0.0462176 1.273386644 EPX 0.006285603 5.018958004
PPME1 0.044805197 1.270752688 GRM5 0.002285614 5.011671892
PPFIA1 0.030380343 1.269463577 CCDC144NL 0.001800777 5.007761853
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HDLBP 0.04553273 1.268867932 PSG6 0.004171012 5.006718997
ANXA5 0.037611537 1.267657764 FOXE1 0.00130328 5.004690831
AKAP9 0.023888134 1.267451155 RAG2 0.002262565 5.000029499
TACC1 0.034247289 1.265661186 ECEL1 0.003285049 4.993426358
ATXN2 0.027654826 1.265372555 RNF182 0.009931228 4.98796644
SEMA4A 0.02772875 1.26386212 NGFR 0.003285049 4.987682282
PHF20L1 0.038305007 1.260046368 ZAN 0.017691706 4.98737387
ARHGEF19 0.022584239 1.256978015 ATP4A 0.005153697 4.987180073
TROVE2 0.04069104 1.256276742 SEZ6L 0.001988926 4.986949264
NDRG2 0.042946809 1.252220154 PCDH7 0.001098212 4.981798786
STK38 0.020763684 1.251905357 FGA 0.004807471 4.979444302
MCCC2 0.04014665 1.250514156 FCGR3B 0.003699197 4.978749472
WDR91 0.04165762 1.248622388 ANO4 0.001348285 4.976237052
ZNF638 0.048096323 1.245970366 BARHL2 0.008909747 4.973689231
PPP1R15A 0.042179781 1.244264956 HPD 0.002058693 4.972097171
SAMD4B 0.02936103 1.242337283 MYO3A 0.010855971 4.971829305
STAT3 0.040194271 1.240659688 PADI3 0.001098212 4.971604495
ITPR3 0.030726281 1.240087474 DNAJB8 0.001863317 4.967738812
SMTN 0.048862168 1.239054329 MMP28 0.00317268 4.967678595
RNF146 0.028950403 1.238586589 ZBED2 0.001413445 4.966551697
PIBF1 0.025233043 1.235180181 TRIM67 0.007284527 4.965743675
STX7 0.042395106 1.233031903 CPNE6 0.002009628 4.960755589
CAPN7 0.048574974 1.232991255 RXRG 0.001199867 4.9499696
SEC16A 0.038786914 1.232449018 KRT6B 0.010766991 4.947313834
DSCAML1 0.032913449 1.230165199 ADAMTS8 0.009614159 4.946010974
ACTR1B 0.031597682 1.228778573 JAML 0.008309788 4.945931692
TCAF1 0.043327116 1.22669069 EMX1 0.002611763 4.944414809
ZC3H14 0.04244593 1.226100003 SLC6A19 0.002097516 4.932191115
NPIPB4 0.011816522 1.224571514 SULT4A1 0.007563643 4.931485898
RBM25 0.043327116 1.221539585 BPIFA2 0.00357002 4.925116468
ZNF783 0.047954934 1.221125736 CKMT2 0.006402439 4.919829765
USP13 0.020987669 1.220925338 CCDC63 0.002518505 4.917744887
SLC25A28 0.045352675 1.215924528 TMCC3 0.001947692 4.917331381
SRSF4 0.035262358 1.214207518 ATP2B2 0.007756243 4.915494755
TRA2A 0.04741087 1.213778563 CHRNA4 0.005872829 4.914794384
ZNF721 0.026976422 1.213238968 FAM151A 0.002493786 4.913582569
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OAZ2 0.049175045 1.212520363 DOCK2 0.009557659 4.90948691
TCF25 0.036623533 1.205715316 SLC13A2 0.001521974 4.906988594
KLHL21 0.028281772 1.205675954 TSPEAR 0.002509996 4.906860843
ASL 0.022021837 1.205556864 KCNS2 0.002487619 4.905869669
NOP58 0.016232331 1.203142875 GJA5 0.01404091 4.90056035
KIF16B 0.041826871 1.201585733 MYLK2 0.001199867 4.897452874
ARIH1 0.027633653 1.200974576 VWF 0.005715706 4.896753883
RNF168 0.034728496 1.197840563 EVA1A 0.004674322 4.893476752
CDC42SE1 0.047756021 1.194494088 MYOD1 0.001944651 4.889753745
SORBS1 0.038292773 1.194376608 DPYS 0.004124374 4.885685694
PACSIN2 0.03187296 1.193654652 SNAP25 0.003752596 4.884990072
KLC1 0.049657674 1.192137019 SPDYE1 0.001435796 4.877456109
PDE4DIP 0.037053654 1.191469348 SPINK5 0.003169733 4.876547735
CREBBP 0.03222394 1.189403267 OSM 0.001947692 4.875568235
CYB5R2 0.040966724 1.189369575 C6orf222 0.001933241 4.87279284
MTCH1 0.019157151 1.188824045 SLC6A5 0.002918453 4.866137741
TMBIM1 0.040265619 1.182519208 FAM92B 0.001348285 4.863335853
HIP1 0.048454027 1.17977456 DUX4 0.003874063 4.861865747
SCAF4 0.029154877 1.178330761 LOXHD1 0.001398736 4.856909471
TNPO2 0.04296147 1.177960462 GRAP2 0.025213475 4.85633186
ZCCHC6 0.04069104 1.177126508 CAPN11 0.005086774 4.854148118
FEM1C 0.022624407 1.176706982 ADAMTS19 0.010635331 4.853307738
TMEM165 0.036084921 1.173753852 PDE9A 0.003588759 4.85325526
AMIGO3 0.027116427 1.172438547 THEMIS 0.001944651 4.852746293
PYGL 0.021737482 1.171103313 INSM2 0.002277115 4.851103975
CSNK1D 0.024315816 1.170781562 CNTNAP4 0.019300088 4.850496046
U2AF2 0.045814496 1.169507635 ANKRD34B 0.004667322 4.843107131
FPGS 0.045798548 1.165024631 SHH 0.005086774 4.837878699
TMEM214 0.02468978 1.163954194 CLRN1 0.001098212 4.837683092
TEP1 0.03665743 1.16239153 GPR182 0.00236758 4.835507051
DYRK1A 0.044145576 1.16136663 SLCO5A1 0.004574148 4.834699095
FZR1 0.040473137 1.160806587 AQP2 0.00277198 4.833516772
NKTR 0.040404538 1.159305433 PRR20C 0.005715706 4.831899841
NISCH 0.023451351 1.156994168 TP73 0.005352304 4.829422133
AP1G1 0.041993567 1.155711392 NR5A1 0.001972068 4.828781103
ACTN4 0.042412359 1.154587927 KRT3 0.00130328 4.828273159
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SENP5 0.0427733 1.15402757 KRT16 0.010251671 4.827288302
CDK9 0.046276534 1.150353282 PCDH8 0.011889341 4.826999809
WDR3 0.031019531 1.149925999 ASXL3 0.003383407 4.825119923
ZSWIM8 0.045988195 1.147046239 GFI1 0.010071831 4.822612891
MSI2 0.043458667 1.146393575 MMP20 0.002918453 4.821707008
PPM1B 0.034631683 1.141966822 CRB3 0.001804147 4.821320662
SMARCA2 0.025213683 1.136144261 PTPRN 0.00261761 4.820549976
NPIPB5 0.039964574 1.135260974 SLFN14 0.001270518 4.820306744
NPIPB11 0.026806925 1.122529524 SFTPA2 0.002277115 4.815910748
YAF2 0.04048315 1.117221516 ARHGAP40 0.011974966 4.814685985
TOM1 0.031597682 1.111751056 ADAMTSL5 0.004171012 4.814242801
FMN1 0.042108084 1.109518007 NWD2 0.01296248 4.812153207
NPIPB13 0.039171252 1.10874638 FOLR3 0.001886172 4.809748807
DCAF8 0.028959282 1.107377705 PGA4 0.003168377 4.808863388
MAP7D1 0.04642451 1.103767991 GIMAP4 0.002918453 4.808486588
LMF2 0.03891096 1.102585809 FETUB 0.008502829 4.807052064
INO80D 0.04659258 1.102307353 PSG11 0.009557659 4.805590894
SPATA6 0.03068145 1.094079414 RXFP1 0.001385184 4.802392523
ERAP1 0.048994512 1.093120555 RLBP1 0.009274205 4.800275322
BCKDHB 0.036823982 1.090569671 CFC1 0.00188708 4.797899327
SS18L1 0.047267162 1.089043302 WDR87 0.003022595 4.795696272
NAPA 0.04250031 1.087370248 TMPRSS9 0.003696065 4.795368549
AGAP6 0.047441751 1.086228843 SH2D1B 0.003268599 4.783820444
EOGT 0.02633916 1.083427737 CHRNA6 0.002009628 4.783451064
STK24 0.045272335 1.081182869 GJB3 0.002009628 4.781404002
YWHAH 0.046578837 1.079128593 RDH12 0.002009628 4.77938888
POLR2J3 0.047861107 1.077883012 IGFN1 0.017060098 4.777157752
SETX 0.028924712 1.07538634 SALL3 0.012694725 4.767330055
BAZ2A 0.042395106 1.073145881 C2orf71 0.00670064 4.761636323
EIF4A1 0.035789771 1.072083402 SLC27A2 0.008102389 4.757151891
SIN3A 0.035047213 1.070629692 DRD1 0.005056309 4.754333833
OSER1 0.046251894 1.067118345 SLCO2B1 0.004807471 4.753797005
ABL1 0.045144563 1.06618123 PCDHA13 0.001973726 4.751344823
STAT5B 0.040536958 1.063440818 CYP1A1 0.001098212 4.75090697
LUC7L 0.030676254 1.062380303 FAM189A1 0.011938646 4.749933665
PTPRG 0.039964574 1.060866811 LYPD6B 0.00261761 4.74978557
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ZNF266 0.044652225 1.056894403 NLRC3 0.001886172 4.748703968
MCTP2 0.039755801 1.054334604 KRT77 0.002533812 4.7465111
TVP23C 0.041179394 1.050174511 HPSE2 0.002485084 4.743660767
CEP63 0.041581717 1.045290603 FBN2 0.020822913 4.739459807
FBXO42 0.031977215 1.038812385 NUTM2G 0.00188708 4.738786302
RNF31 0.027633653 1.03338765 CCDC188 0.001857007 4.738121563
METTL16 0.043830946 1.028837893 EPHA8 0.003285049 4.736280623
EFCAB1 0.045454203 1.026899938 RAG1 0.005290573 4.734588933
MTMR3 0.046828942 1.025063794 SSC4D 0.004569339 4.732073795
DHX15 0.040404538 1.021747117 SPATA31D1 0.006197788 4.729439526
EP300 0.045537885 1.021299507 KCNV2 0.001825737 4.726161862
ANTXR2 0.044887925 1.017695962 CD8A 0.008577972 4.723890059
SND1 0.036130832 1.014848855 SERPINB13 0.003752596 4.720386986
CCNK 0.036084921 1.002674551 ZNF536 0.002009628 4.717768157
ASXL1 0.03352273 1.001805506 DNAAF3 0.00188708 4.71437315
CLK2 0.044989407 0.995547274 CWH43 0.001712362 4.71174779
GPATCH8 0.047525421 0.995492137 CLDN19 0.00178501 4.710877897
CRTC2 0.039294744 0.993615351 TRPC7 0.002905025 4.710321255
ZNF326 0.023654834 0.990905795 HTR7 0.00447874 4.707893933
TRABD 0.04165762 0.990335449 MEP1A 0.0080853 4.705584745
ABCF3 0.034513072 0.982542287 MYH2 0.010855971 4.70461446
SAP30BP 0.038786914 0.972432806 SUN5 0.00261761 4.701158958
GOLGA4 0.044805197 0.966826369 PIRT 0.002277115 4.699819525
PPP6R2 0.046283742 0.961824566 OCSTAMP 0.002485084 4.698157711
GMPPB 0.045272335 0.960836184 ZP4 0.00305044 4.693757668
GABPB2 0.049172728 0.95725764 C12orf42 0.011834336 4.689900496
ARFGAP3 0.047650269 0.953204297 HABP2 0.005715706 4.688954525
POMGNT1 0.044652225 0.951642523 TP53TG3 0.003970356 4.686098996
ADAM17 0.045459049 0.947157631 LRRC4B 0.002918453 4.685112827
ZFC3H1 0.04199409 0.927250471 VTCN1 0.003285049 4.683013899
EIF4G1 0.049945735 0.919193851 INSRR 0.016870554 4.681321249
DUS1L 0.04659258 0.91802603 WNT3A 0.00236758 4.681306229
PI4KB 0.045810037 0.902182083 DCAF4L2 0.01409258 4.678724657
NCOA1 0.044448914 0.888720425 RGS8 0.02938624 4.673690794
IRX6 0.013384037 4.668674359
MYRIP 0.005008576 4.668508408
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mtDNA: mitochondrial DNA; logFc: log fold change; adj. p-value: adjusted p-values calculated by Benjamini & 
Hochberg´s method for false discovery rate (FDR) control
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Supplementary figure 1.  Genomic location of DMLs between haplogroups H and J. Percentage of DMLs 
between haplogroups H and J on each of the genomic locations attending to the chromatin states described 
in the Roadmap Epigenomics Consortium. TssA: Active transcription start site; TssAFlnk: Transcription at 
gene 5´and 3´; TxFlnk: Strong transcription; TxWk: Weak transcription; Enh: Enhancers; TssBiv: 
Bivalent/Poised transcription start site; BivFlnk: Flanking bivalent Tss/Enh; ReprPC: Repressed PolyComb; 
ReprPCWk: Weak repressed PolyComb; Quies: Quiescent/low 
94x80mm (300 x 300 DPI) 
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